"molregno","standard_inchi","canonical_smiles","SAMPLE","activity_id","assay_id","doc_id","record_id","standard_relation","standard_value","standard_units","standard_flag","standard_type","activity_comment","data_validity_comment","description","assay_type","assay_test_type","assay_category","assay_organism","assay_tax_id","assay_strain","assay_tissue","assay_cell_type","assay_subcellular_fraction","tid","relationship_type","confidence_score","curated_by","src_id","src_assay_id","chembl_id","target_type","pref_name","tax_id","organism","species_group_flag","Iteration","RankSantiagoFloriane","RankSereina","cScore","rSquared","ec50","ec50_l","ec50_u","EMOLECULES_ID","supplier","CATALOG_NUMBER"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",14762808,1369278,84147,2128254,,2.9,,0,"LogD7.4",,,"Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5","P",,,,,,,,,22224,"U",0,"Autocuration",27,"2","CHEMBL3301363","ADMET","ADMET",,,0,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",14763436,1369287,84147,2128254,,32.36,"uL.min-1.(10^6cells)-1",1,"CL",,,"Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.","A","In vitro",,"Homo sapiens",9606,,"Liver","Hepatocyte",,22224,"U",0,"Autocuration",27,"11","CHEMBL3301372","ADMET","ADMET",,,0,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
29097,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)","CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O","SJ000110703-13",14766550,1369285,84147,2128254,">",150.0,"mL.min-1.g-1",1,"CL",,,"Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.","A","In vitro",,"Homo sapiens",9606,,"Liver",,"Microsomes",22224,"U",0,"Autocuration",27,"9","CHEMBL3301370","ADMET","ADMET",,,0,0,853,,"A Active",0.98,0.025,0.023,0.031,6720220,"ENAMINE","Z1552192759"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3035373,600888,49165,864306,"=",7.3,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3037377,600887,49165,864306,"=",8670.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3039554,600886,49165,864306,"=",106.5,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3040815,600885,49165,864306,"=",212.5,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3047315,600890,49166,870542,,7389.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",3050806,600889,49166,870542,,1307.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237269,726822,55744,1335104,"=",92.93,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686422","CELL-LINE","HT-29",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237287,726823,55744,1335104,"=",89.28,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686423","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237305,726824,55744,1335104,"=",92.33,"%",1,"Inhibition",,,"Anticancer activity against human SKOV3 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",1,,"CHEMBL1686424","CELL-LINE","SK-OV-3",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237333,726826,55744,1335104,"=",21300.0,"nM",1,"IC50",,,"Anticancer activity against human DU145 cells by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686426","CELL-LINE","DU-145",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237351,726827,55744,1335104,"=",13400.0,"nM",1,"IC50",,,"Anticancer activity against human HT-29 cells by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686427","CELL-LINE","HT-29",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237379,726831,55744,1335104,"=",52.21,"%",1,"Inhibition",,,"Anticancer activity against human DU145 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686431","CELL-LINE","DU-145",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237387,726832,55744,1335104,"=",80.65,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686432","CELL-LINE","HT-29",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",5237395,726919,55744,1335104,"=",81.16,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686708","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",6233932,752282,57966,1431952,,,,0,"Activity","Active",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",6234102,752283,57966,1431952,"=",305.4,"nM",1,"IC50",,,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",6234735,752283,57966,1431952,"=",29.96,"um",0,"Schizont size","47.83 pixels",,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10879426,817943,61889,1640633,"=",1007.03,"nM",1,"IC50",,,"MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro.","F","In vitro",,"Leishmania infantum",5671,"MHOM/MA/BE/67",,,,50417,"N",1,"Autocuration",17,"8","CHEMBL2028076","ORGANISM","Leishmania infantum",5671,"Leishmania infantum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10879826,817944,61889,1640633,"=",12381.69,"nM",1,"IC50",,,"MMV: Cytotoxicity against human fibroblasts (MRC-5) cells.","T","In vitro",,"Homo sapiens",9606,,,"MRC5",,80291,"N",1,"Autocuration",17,"9","CHEMBL2028077","CELL-LINE","MRC5",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10880723,817938,61889,1640633,"=",589.0,"nM",1,"EC50",,,"MMV: Inhibition of Plasmodium falciparum 3D7 (EC50).","F","In vitro",,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",17,"3","CHEMBL2028071","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10881048,817940,61889,1640633,"=",3551.85,"nM",1,"IC50",,,"MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro).","F","In vitro",,"Trypanosoma cruzi",5693,"Tulahuen C4 (LacZ)",,,,50466,"N",1,"Autocuration",17,"5","CHEMBL2028073","ORGANISM","Trypanosoma cruzi",5693,"Trypanosoma cruzi",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10881448,817941,61889,1640633,"=",3836.42,"nM",1,"IC50",,,"MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro).","F","In vitro",,"Trypanosoma brucei brucei",5702,"Squib 427",,,,50420,"N",1,"Autocuration",17,"6","CHEMBL2028074","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",10881848,817942,61889,1640633,"=",4028.1,"nM",1,"IC50",,,"MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro).","F","In vitro",,"Trypanosoma brucei rhodesiense",31286,"STIB 900",,,,50725,"N",1,"Autocuration",17,"7","CHEMBL2028075","ORGANISM","Trypanosoma brucei rhodesiense",31286,"Trypanosoma brucei rhodesiense",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031230,842692,65069,1677889,"=",48700.0,"nM",1,"MIC90",,,"MMV: CRC and MIC90 against Mtb (non replicating)","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"3","CHEMBL2094263","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031285,842693,65069,1677889,"=",7330.0,"nM",1,"MIC90",,,"MMV: CRC and MIC90 against Mtb (replicating)","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"4","CHEMBL2094264","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031342,842694,65069,1677889,"=",2.59,"uM",0,"LD50",,"Non standard unit for type","MMV: Cytotoxicity CRC and LD50 against HepG2","T","In vitro",,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",17,"5","CHEMBL2094265","CELL-LINE","HepG2",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031581,842690,65069,1677889,"=",53.9,"%",1,"Inhibition",,,"MMV: Screen against Mtb, single point, non replicating, at 25uM","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"1","CHEMBL2094261","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",11031980,842691,65069,1677889,"=",98.0,"%",1,"Inhibition",,,"MMV: Screen against Mtb, single point, replicating, at 25uM","F","In vitro",,"Mycobacterium tuberculosis",1773,,,,,50309,"N",1,"Autocuration",17,"2","CHEMBL2094262","ORGANISM","Mycobacterium tuberculosis",1773,"Mycobacterium tuberculosis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13200581,954364,72898,1877950,"=",2.0,,0,"Toxicity","Round, overactive",,"MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 24 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"1","CHEMBL2363023","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13200981,954365,72898,1877950,"=",4.0,,0,"Toxicity","Round, degenerate, slow",,"MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 48 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"2","CHEMBL2363024","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201381,954366,72898,1877950,"=",4.0,,0,"Toxicity","Dead",,"MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 72 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"3","CHEMBL2363025","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201595,954367,72898,1877950,"=",0.0,,0,"Toxicity","No effect",,"MMV: Toxicity @ 5 uM to 4-5 Schistosoma mansoni adult males after 24 h on a scale of 0 (none) - 4 (most). Includes short descriptors of effects as judged visually (PMID:19597541). Only those Malaria box 'drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"4","CHEMBL2363026","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201636,954368,72898,1877950,"=",0.0,,0,"Toxicity","No effect",,"MMV: Toxicity @ 5 uM to 4-5 Schistosoma mansoni adult males after 48 h on a scale of 0 (none) - 4 (most). Includes short descriptors of effects as judged visually (PMID:19597541). Only those Malaria box 'drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"5","CHEMBL2363027","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201676,954369,72898,1877950,"=",0.0,,0,"Toxicity","No effect",,"MMV: Toxicity @ 5 uM to 4-5 Schistosoma mansoni adult males after 72 h on a scale of 0 (none) - 4 (most). Includes short descriptors of effects as judged visually (PMID:19597541). Only those Malaria box 'drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"6","CHEMBL2363028","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201716,954370,72898,1877950,"=",100.0,,0,"Motility","No effect",,"MMV: Motility assay. Percent change (relative to DMSO controls) @ 5 uM of movement of 4-5 Schistosoma mansoni adult males after 24 h as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493). Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'. In these cases the 'toxicity score' should be prioritized. Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"7","CHEMBL2363029","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201757,954371,72898,1877950,"=",105.7,,0,"Motility","No effect",,"MMV: Motility assay. Percent change (relative to DMSO controls) @ 5 uM of movement of 4-5 Schistosoma mansoni adult males after 48 h as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493). Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'. In these cases the 'toxicity score' should be prioritized. Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"8","CHEMBL2363030","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13201797,954372,72898,1877950,,,,0,"Motility","No effect",,"MMV: Motility assay. Percent change (relative to DMSO controls) @ 5 uM of movement of 4-5 Schistosoma mansoni adult males after 72 h as measured by the Consensus Voting Luminance Difference algorithm available on WormAssay (PMID:22303493). Occasional incongruence ocurrs between the motility scores and the visually adjudicated 'toxicity scores'. In these cases the 'toxicity score' should be prioritized. Only those Malaria box 'Drug-like' cpds yielding the most severe phenotypes vs. somules were tested. Caffrey group UCSF.","F","In vitro",,"Schistosoma mansoni",6183,,,,,50479,"N",1,"Autocuration",17,"9","CHEMBL2363031","ORGANISM","Schistosoma mansoni",6183,"Schistosoma mansoni",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13517415,993477,75427,1931987,"=",1.09,,0,"Ratio",,,"MMV: Compounds (1uM) were screened in a 72hr growth assay monitored by flow cytometry both in the presence and absence of supplemental isopentenyl pyrophosphate (IPP) 200uM. Compounds which fail to show anti-malarial activity when chemically rescued by IPP are therefore specific to the apicoplast. The values are expressed as the ratio of the corresponding activity with and without IPP, respectively.","F","In vitro",,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",17,"1","CHEMBL2448810","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13976379,1301162,77387,1977269,"=",49.98,"%",1,"Inhibition",,,"MMV: Cryptosporidium parvum oocysts (Iowa Strain) were prepared for use by treatment with 10 mM HCl (37 degrees C, 10 min) followed by 2 mM sodium taurocholate in phosphate-buffered saline (PBS) with Ca2+ and Mg2+ (16 degrees C, 10 min) in order to stimulate excystation. The high-throughput screen was carried out by inoculating >90% confluent human ileocecal adenocarcinoma (HCT-8) cells (ATCC) with ~5.5 x 10^3 primed oocysts per well. Experimental compounds or DMSO (vehicle) were added three hours after infection, and cells were incubated for 48 hours.","F","In vitro",,"Cryptosporidium parvum",5807,"Iowa",,"HCT-8",,50424,"N",1,"Autocuration",17,"1","CHEMBL3137357","ORGANISM","Cryptosporidium parvum",5807,"Cryptosporidium parvum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13976584,1301182,77406,1977662,"=",204.44,"nM",1,"IC50",,,"MMV: Growth inhibition of P. falciparum cultures was quantified using a parasite lactate dehydrogenase (LDH) assay. The cultures were diluted to 0.5% parasitemea and 2% hematocrit and subjected to each twofold serial dilutions of the compounds for 72 h (DMSO final concentration, 0.25%). After 72 h, the cultures were frozen. LDH activity of P. falciparum parasites in aliquots of freeze-thawed cultures was spectrophotometrically measured and the IC50s were determined.","F","In vitro",,"Plasmodium falciparum",5838,"FCR3",,,,50425,"N",1,"Autocuration",17,"1","CHEMBL3137362","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13977238,1301262,77446,1978686,"=",33.33,"%",0,"Motility","Activity score: 2.0",,"MMV: Percent motility assay at a compound concentration of 1.25e-5 M. Activity score legend: 3: Active, 2: Moderately active; 1: Inactive, 0: Toxic","F","In vitro",,"Onchocerca lienalis",263205,,,,,104676,"N",1,"Autocuration",17,"1","CHEMBL3137382","ORGANISM","Onchocerca lienalis",263205,"Onchocerca lienalis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13977637,1301263,77446,1978686,"=",100.0,"%",0,"Motility","Activity score: 1.0",,"MMV: Percent motility assay at a compound concentration of 3.1e-6 M. Activity score legend: 3: Active, 2: Moderately active; 1: Inactive, 0: Toxic","F","In vitro",,"Onchocerca lienalis",263205,,,,,104676,"N",1,"Autocuration",17,"2","CHEMBL3137383","ORGANISM","Onchocerca lienalis",263205,"Onchocerca lienalis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13978036,1301264,77446,1978686,"=",100.0,"%",0,"Motility","Activity score: 1.0",,"MMV: Percent motility assay at a compound concentration of 1.9e-7 M. Activity score legend: 3: Active, 2: Moderately active; 1: Inactive, 0: Toxic","F","In vitro",,"Onchocerca lienalis",263205,,,,,104676,"N",1,"Autocuration",17,"3","CHEMBL3137384","ORGANISM","Onchocerca lienalis",263205,"Onchocerca lienalis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",13978435,1301265,77446,1978686,"=",100.0,"%",0,"Motility","Activity score: 1.0",,"MMV: Percent motility assay at a compound concentration of 7.8e-7 M. Activity score legend: 3: Active, 2: Moderately active; 1: Inactive, 0: Toxic","F","In vitro",,"Onchocerca lienalis",263205,,,,,104676,"N",1,"Autocuration",17,"4","CHEMBL3137385","ORGANISM","Onchocerca lienalis",263205,"Onchocerca lienalis",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14772845,1369308,84167,2133793,">",30000.0,"nM",1,"IC50",,,"MMV: Primary screening was performed with each compound at a 30 uM final concentration and in triplicate in sealed 96-well polystyrene microtiter plates. Parasite inocula (100 ul) comprising 20000 parasites/ml were added to each well and grown at 37Â°C in a humidified atmosphere of 5% CO2 for 72 h. Positive controls consisted of metronidazole at 1 mg/ml. The growth of E. histolytica trophozoites in each well was determined microscopically by measuring the diameters of the confluent cells in drug-containing wells relative to those in the nega- tive-control wells.","F",,,"Entamoeba histolytica",5759,,,,,50422,"N",1,"Autocuration",17,"1","CHEMBL3301449","ORGANISM","Entamoeba histolytica",5759,"Entamoeba histolytica",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14773245,1369309,84167,2133793,">",30000.0,"nM",1,"IC50",,,"MMV: A total of 100ul of inoculum was added to each well (parasite/cell ratio, ~10:1; final volume, 200 ul). Six hours after inoculation, nonadherent parasites were removed, and 100 ul of complete DMEM (1% penicillin-streptomycin, 3% FBS) supplemented with inhibitors at different concentrations (2-fold serial dilutions starting from 30 uM) was added to all except the negative-control wells. Positive controls, consisting of pyrimethamine (PYR) and sulfadiazine (SDZ) (20-mg/ml stocks in DMSO), were tested at a 2mg/ml final concentration. Each test was performed in triplicate.","F",,,"Toxoplasma gondii",5811,,,,,50472,"N",1,"Autocuration",17,"2","CHEMBL3301450","ORGANISM","Toxoplasma gondii",5811,"Toxoplasma gondii",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14773697,1369310,84168,2134490,"=",-12.8,"%",1,"Inhibition",,"Outside typical range","MMV: P. berghei-infected blood was withdrawn from mice by cardiac pucture before being immediately added to ookinete culture medium containing test compounds. 26 hr later, GFP-positive ookinetes were identified and counted by automated microscopy. All compounds were tested in 4 independent experiments and data presented here is the mean.","F","In vitro",,"Plasmodium berghei",5821,,,,,50473,"N",1,"Autocuration",17,"1","CHEMBL3301452","ORGANISM","Plasmodium berghei",5821,"Plasmodium berghei",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14774183,1369312,84168,2134490,"=",-30.2,"%",1,"Inhibition",,"Outside typical range","MMV: P. falciparum NF54 functionally mature Stage V gametocytes were incubated for 24 hr in the presence of the test compounds. Gamete formation was then triggered by addition of 2uM xantheurenic acid and temperature decrease to ~20C. Male gamete exflagellation was recorded and analysed by automated microscopy after 20 min. All compounds were tested in 4 independent experiments and data presented here is the mean.","F","In vitro",,"Plasmodium falciparum",5833,"NF54",,,,50425,"N",1,"Autocuration",17,"3","CHEMBL3301454","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14774583,1369313,84168,2134490,"=",-14.7,"%",1,"Inhibition",,"Outside typical range","MMV: P. falciparum NF54 functionally mature Stage V gametocytes were incubated for 24 hr in the presence of the test compounds. Gamete formation was then triggered by addition of 2uM xantheurenic acid and temperature decrease to ~20C. Female gamete formation was recorded 24 hr later by automated microscopy detection of surface labelling of female gametes with a Cy3-conjugated antibody reactive to Pfs25. All compounds were tested in 4 independent experiments and data presented here is the mean.","F","In vitro",,"Plasmodium falciparum",5833,"NF54",,,,50425,"N",1,"Autocuration",17,"4","CHEMBL3301455","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14774695,1369316,84169,2134704,"=",0.0,"%",1,"Inhibition",,,"MMV: Malaria Box compounds were tested for inhibition of the human ether a go-go related gene (hERG), Kv11.1 channel, using IonWorks 384-well patch clamp electrophysiology at 1.1uM (3 independent assay plates up to 12 cells per concentration).","F","In vitro",,"Homo sapiens",9606,,,,,165,"D",9,"Autocuration",17,"1","CHEMBL3301459","SINGLE PROTEIN","HERG",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14775095,1369317,84169,2134704,"=",53.0,"%",1,"Inhibition","Active",,"MMV: Malaria Box compounds were tested for inhibition of the human ether a go-go related gene (hERG), Kv11.1 channel, using IonWorks 384-well patch clamp electrophysiology at 11.1uM (3 independent assay plates up to 12 cells per concentration).","F","In vitro",,"Homo sapiens",9606,,,,,165,"D",9,"Autocuration",17,"2","CHEMBL3301460","SINGLE PROTEIN","HERG",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14775483,1369319,84170,2135069,"=",2.4,"degrees C",0,"delta T (thermal shift)",,,"MMV: Thermal shift assay for identifying inhibitors","B",,,"Plasmodium falciparum",5833,"3D7",,,,22226,"U",0,"Autocuration",17,"2","CHEMBL3301463","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14775670,1369320,84171,2135459,"=",60.0,"nM",1,"IC50",,,"MMV: Anti-babesial activity assay. Parasite pRBCs at 1% parasitemia were cultivated in 100 ul with 96-well plates at 2.5% and 5% hematocrits. The parasites were cultivated in triplicate for 4 days without replacement of the medium for each concentration of the compound. On the fourth day of culture, lysis buffer containing 2x SGI was added and 50% inhibitory concentration (IC50) values were calculated.","F","In vitro",,"Babesia bovis",5865,,,,,22226,"U",0,"Autocuration",17,"1","CHEMBL3301465","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14775882,1369323,84171,2135459,"=",3700.0,"nM",1,"IC50",,,"MMV: Anti-babesial activity assay. Parasite pRBCs at 1% parasitemia were cultivated in 100 ul with 96-well plates at 2.5% and 5% hematocrits. The parasites were cultivated in triplicate for 4 days without replacement of the medium for each concentration of the compound. On the fourth day of culture, lysis buffer containing 2x SGI was added and 50% inhibitory concentration (IC50) values were calculated.","F","In vitro",,"Babesia caballi",5871,,,,,22226,"U",0,"Autocuration",17,"4","CHEMBL3301468","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14776377,1369321,84171,2135459,"=",2160.0,"nM",1,"IC50",,,"MMV: Anti-babesial activity assay. Parasite pRBCs at 1% parasitemia were cultivated in 100 ul with 96-well plates at 2.5% and 5% hematocrits. The parasites were cultivated in triplicate for 4 days without replacement of the medium for each concentration of the compound. On the fourth day of culture, lysis buffer containing 2x SGI was added and 50% inhibitory concentration (IC50) values were calculated.","F","In vitro",,"Babesia bigemina",5866,,,,,22226,"U",0,"Autocuration",17,"2","CHEMBL3301466","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14776738,1369322,84171,2135459,"=",4770.0,"nM",1,"IC50",,,"MMV: Anti-babesial activity assay. Parasite pRBCs at 1% parasitemia were cultivated in 100 ul with 96-well plates at 2.5% and 5% hematocrits. The parasites were cultivated in triplicate for 4 days without replacement of the medium for each concentration of the compound. On the fourth day of culture, lysis buffer containing 2x SGI was added and 50% inhibitory concentration (IC50) values were calculated.","F","In vitro",,"Babesia equi",5872,,,,,22226,"U",0,"Autocuration",17,"3","CHEMBL3301467","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14777326,1369334,84173,2136227,"=",-17500.0,"%",1,"Inhibition",,"Outside typical range","MMV: HIV JRFL CCR5-tropic replication-competent virus, NO washout, P24 ELISA Day 7 pi, U87-CD4-CCR5, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"JR-FL",,"U87-CD4-CCR5",,50607,"N",1,"Autocuration",17,"10","CHEMBL3301482","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14777655,1369325,84173,2136227,"=",-4800.0,"%",1,"Inhibition",,"Outside typical range","MMV: HIV CCR5-tropic env JRFL pseudovirus assay produces luciferase signal in lieu of replicating viral particles Day 3 pi, U87-CD4-CCR5, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"JR-FL",,"U87-CD4-CCR5",,50607,"N",1,"Autocuration",17,"1","CHEMBL3301473","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14778332,1369326,84173,2136227,"=",5500.0,"%",1,"Inhibition",">50","Outside typical range","MMV: HIV CXCR4-tropic env NL4-3 pseudovirus assay produces luciferase signal in lieu of replicating viral particles Day 3 pi, U87-CD4-CXCR4, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"NL4-3",,"U87-CD4-CXCR4",,50607,"N",1,"Autocuration",17,"2","CHEMBL3301474","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14778582,1369335,84173,2136227,"=",7300.0,"%",1,"Inhibition",">50","Outside typical range","MMV: HIV NL4-3 CXCR4-tropic replication-competent virus, NO washout, P24 ELISA Day 7 pi, U87-CD4-CXCR4, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"NL4-3",,"U87-CD4-CXCR4",,50607,"N",1,"Autocuration",17,"11","CHEMBL3301483","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14779010,1369327,84173,2136227,"=",-8000.0,"%",1,"Inhibition",,"Outside typical range","MMV: HIV CXCR4-tropic env HxB2 pseudovirus assay produces luciferase signal in lieu of replicating viral particles Day 3 pi, U87-CD4-CXCR4, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"HxB2",,"U87-CD4-CXCR4",,50607,"N",1,"Autocuration",17,"3","CHEMBL3301475","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14779267,1369336,84173,2136227,"=",41.0,,0,"% Cell Death",,,"MMV: MTT Cytotoxicity Assay Day 7 pi of Assay #10 (NO washout), U87-CD4-CCR5 cells, % cell death @ 5mM compound","F","In vitro",,"Homo sapiens",9606,,,"U87-CD4-CCR5",,22226,"U",0,"Autocuration",17,"12","CHEMBL3301484","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14779955,1369337,84173,2136227,"=",-24.0,,0,"% Cell Death",,,"MMV: MTT Cytotoxicity Assay Day 7 pi of Assay #11 (NO washout), U87-CD4-CXCR4 cells, % cell death @ 5mM compound","F","In vitro",,"Homo sapiens",9606,,,"U87-CD4-CXCR4",,22226,"U",0,"Autocuration",17,"13","CHEMBL3301485","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14779971,1369328,84173,2136227,"=",18.0,,0,"% Cell Death",,,"MMV: MTT Cytotoxicity Assay Day 3 pi, U87-CD4-CCR5 cells, % cell death @ 5mM compound","F","In vitro",,"Homo sapiens",9606,,,"U87-CD4-CCR5",,22226,"U",0,"Autocuration",17,"4","CHEMBL3301476","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14780526,1369329,84173,2136227,"=",28.0,,0,"% Cell Death",,,"MMV: MTT Cytotoxicity Assay Day 3 pi, U87-CD4-CXCR4 cells, % cell death @ 5mM compound","F","In vitro",,"Homo sapiens",9606,,,"U87-CD4-CXCR4",,22226,"U",0,"Autocuration",17,"5","CHEMBL3301477","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14780926,1369330,84173,2136227,"=",200.0,"%",1,"Inhibition",,"Outside typical range","MMV: HIV JRFL CCR5-tropic replication-competent virus, virus & compound washed out Day 1 pi, P24 ELISA Day 7 pi, U87-CD4-CCR5, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"JR-FL",,"U87-CD4-CCR5",,50607,"N",1,"Autocuration",17,"6","CHEMBL3301478","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14781326,1369331,84173,2136227,"=",5500.0,"%",1,"Inhibition",">50","Outside typical range","MMV: HIV NL4-3 CXCR4-tropic replication-competent virus, virus & compound washed out Day 1 pi, P24 ELISA Day 7 pi, U87-CD4-CXCR4, % inhibition at 5 mM compound","F","In vitro",,"Human immunodeficiency virus 1",11676,"NL4-3",,"U87-CD4-CXCR4",,50607,"N",1,"Autocuration",17,"7","CHEMBL3301479","ORGANISM","Human immunodeficiency virus 1",11676,"Human immunodeficiency virus 1",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14781726,1369332,84173,2136227,"=",21.0,,0,"% Cell Death",,,"MMV: MTT Cytotoxicity Assay Day 7 pi of Assay #6 (compound washed out Day 1 pi), U87-CD4-CCR5 cells, % cell death @ 5mM compound","F","In vitro",,"Homo sapiens",9606,,,"U87-CD4-CCR5",,22226,"U",0,"Autocuration",17,"8","CHEMBL3301480","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14782126,1369333,84173,2136227,"=",-30.0,,0,"% Cell Death",,,"MMV: MTT Cytotoxicity Assay Day 7 pi of Assay #7 (compound washed out Day 1 pi), U87-CD4-CXCR4 cells, % cell death @ 5mM compound","F","In vitro",,"Homo sapiens",9606,,,"U87-CD4-CXCR4",,22226,"U",0,"Autocuration",17,"9","CHEMBL3301481","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14782175,1369381,84174,2136593,"=",39.67,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line NCI/ADR-RES","F","In vitro",,"Homo sapiens",9606,,,"NCI/ADR-RES",,80711,"N",1,"Autocuration",17,"44","CHEMBL3301530","CELL-LINE","NCI/ADR-RES",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14782755,1369340,84174,2136593,"=",67.35,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Breast Cancer cell line MCF7","F","In vitro",,"Homo sapiens",9606,,,"MCF7",,80224,"N",1,"Autocuration",17,"3","CHEMBL3301489","CELL-LINE","MCF7",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14783772,1369382,84174,2136593,"=",14.77,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line OVCAR-3","F","In vitro",,"Homo sapiens",9606,,,"OVCAR-3",,80354,"N",1,"Autocuration",17,"45","CHEMBL3301531","CELL-LINE","OVCAR-3",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14783959,1369392,84174,2136593,"=",35.66,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line CAKI-1","F","In vitro",,"Homo sapiens",9606,,,"CAKI-1",,80055,"N",1,"Autocuration",17,"55","CHEMBL3301541","CELL-LINE","CAKI-1",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14784348,1369393,84174,2136593,"=",14.53,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line RXF 393","F","In vitro",,"Homo sapiens",9606,,,"RXF 393",,80438,"N",1,"Autocuration",17,"56","CHEMBL3301542","CELL-LINE","RXF 393",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14784500,1369394,84174,2136593,"=",69.46,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line SN12C","F","In vitro",,"Homo sapiens",9606,,,"SN12C",,80498,"N",1,"Autocuration",17,"57","CHEMBL3301543","CELL-LINE","SN12C",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14784804,1369396,84174,2136593,"=",58.89,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line UO-31","F","In vitro",,"Homo sapiens",9606,,,"UO-31",,80575,"N",1,"Autocuration",17,"59","CHEMBL3301545","CELL-LINE","UO-31",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14785263,1369351,84174,2136593,"=",91.49,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line HCC-2998","F","In vitro",,"Homo sapiens",9606,,,"HCC-2998",,22226,"U",0,"Autocuration",17,"14","CHEMBL3301500","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14785488,1369361,84174,2136593,"=",75.86,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Leukemia cell line RPMI-8226","F","In vitro",,"Homo sapiens",9606,,,"RPMI-8226",,80433,"N",1,"Autocuration",17,"24","CHEMBL3301510","CELL-LINE","RPMI-8226",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14785685,1369371,84174,2136593,"=",65.28,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line UACC-62","F","In vitro",,"Homo sapiens",9606,,,"UACC-62",,80570,"N",1,"Autocuration",17,"34","CHEMBL3301520","CELL-LINE","UACC-62",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14786872,1369341,84174,2136593,"=",41.0,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Breast Cancer cell line MDA-MB-231/ATCC","F","In vitro",,"Homo sapiens",9606,,,"MDA-MB-231/ATCC",,22226,"U",0,"Autocuration",17,"4","CHEMBL3301490","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14787825,1369372,84174,2136593,"=",21.95,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line A549/ATCC","F","In vitro",,"Homo sapiens",9606,,,"A549/ATCC",,22226,"U",0,"Autocuration",17,"35","CHEMBL3301521","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14787893,1369383,84174,2136593,"=",-37.2,"%",1,"Inhibition",,"Outside typical range","MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line OVCAR-4","F","In vitro",,"Homo sapiens",9606,,,"OVCAR-4",,80355,"N",1,"Autocuration",17,"46","CHEMBL3301532","CELL-LINE","OVCAR-4",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14788131,1369395,84174,2136593,"=",40.56,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line TK-10","F","In vitro",,"Homo sapiens",9606,,,"TK-10",,80551,"N",1,"Autocuration",17,"58","CHEMBL3301544","CELL-LINE","TK-10",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14788566,1369342,84174,2136593,"=",40.15,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Breast Cancer cell line MDA-MB-468","F","In vitro",,"Homo sapiens",9606,,,"MDA-MB-468",,80244,"N",1,"Autocuration",17,"5","CHEMBL3301491","CELL-LINE","MDA-MB-468",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14788685,1369352,84174,2136593,"=",29.77,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line HCT-116","F","In vitro",,"Homo sapiens",9606,,,"HCT-116",,80928,"N",1,"Autocuration",17,"15","CHEMBL3301501","CELL-LINE","HCT-116",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14788925,1369362,84174,2136593,"=",45.22,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Leukemia cell line SR","F","In vitro",,"Homo sapiens",9606,,,"SR",,81325,"N",1,"Autocuration",17,"25","CHEMBL3301511","CELL-LINE","SR",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14789525,1369384,84174,2136593,"=",78.74,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line OVCAR-5","F","In vitro",,"Homo sapiens",9606,,,"OVCAR-5",,80356,"N",1,"Autocuration",17,"47","CHEMBL3301533","CELL-LINE","OVCAR-5",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14790081,1369353,84174,2136593,"=",72.42,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line HCT-15","F","In vitro",,"Homo sapiens",9606,,,"HCT-15",,81335,"N",1,"Autocuration",17,"16","CHEMBL3301502","CELL-LINE","HCT-15",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14790316,1369363,84174,2136593,"=",46.82,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line LOX IMVI","F","In vitro",,"Homo sapiens",9606,,,"LOX IMVI",,22226,"U",0,"Autocuration",17,"26","CHEMBL3301512","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14790518,1369373,84174,2136593,"=",-48.0,"%",1,"Inhibition",,"Outside typical range","MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line HOP-62","F","In vitro",,"Homo sapiens",9606,,,"HOP-62",,81201,"N",1,"Autocuration",17,"36","CHEMBL3301522","CELL-LINE","HOP-62",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14790950,1369343,84174,2136593,"=",45.62,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Breast Cancer cell line T-47D","F","In vitro",,"Homo sapiens",9606,,,"T-47D",,22226,"U",0,"Autocuration",17,"6","CHEMBL3301492","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14791917,1369385,84174,2136593,"=",6.75,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line OVCAR-8","F","In vitro",,"Homo sapiens",9606,,,"OVCAR-8",,80357,"N",1,"Autocuration",17,"48","CHEMBL3301534","CELL-LINE","OVCAR-8",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14792341,1369344,84174,2136593,"=",31.26,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human CNS Cancer cell line SF-268","F","In vitro",,"Homo sapiens",9606,,,"SF-268",,81054,"N",1,"Autocuration",17,"7","CHEMBL3301493","CELL-LINE","SF-268",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14792464,1369354,84174,2136593,"=",49.03,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line HT29","F","In vitro",,"Homo sapiens",9606,,,"HT29",,22226,"U",0,"Autocuration",17,"17","CHEMBL3301503","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14792676,1369364,84174,2136593,"=",76.95,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line M14","F","In vitro",,"Homo sapiens",9606,,,"M14",,80214,"N",1,"Autocuration",17,"27","CHEMBL3301513","CELL-LINE","M14",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14792909,1369374,84174,2136593,"=",-4.85,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line HOP-92","F","In vitro",,"Homo sapiens",9606,,,"HOP-92",,80972,"N",1,"Autocuration",17,"37","CHEMBL3301523","CELL-LINE","HOP-92",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14793311,1369386,84174,2136593,"=",13.42,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line SK-OV-3","F","In vitro",,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",17,"49","CHEMBL3301535","CELL-LINE","SK-OV-3",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14793859,1369355,84174,2136593,"=",80.73,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line KM12","F","In vitro",,"Homo sapiens",9606,,,"KM12",,80192,"N",1,"Autocuration",17,"18","CHEMBL3301504","CELL-LINE","KM12",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14794069,1369365,84174,2136593,"=",39.72,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line MALME-3M","F","In vitro",,"Homo sapiens",9606,,,"MALME-3M",,81248,"N",1,"Autocuration",17,"28","CHEMBL3301514","CELL-LINE","Malme-3M",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14794268,1369375,84174,2136593,"=",6.99,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line NCI-H226","F","In vitro",,"Homo sapiens",9606,,,"NCI-H226",,81280,"N",1,"Autocuration",17,"38","CHEMBL3301524","CELL-LINE","NCI-H226",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14794715,1369345,84174,2136593,"=",19.62,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human CNS Cancer cell line SF-295","F","In vitro",,"Homo sapiens",9606,,,"SF-295",,80468,"N",1,"Autocuration",17,"8","CHEMBL3301494","CELL-LINE","SF-295",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14795439,1369376,84174,2136593,"=",77.25,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line NCI-H23","F","In vitro",,"Homo sapiens",9606,,,"NCI-H23",,81281,"N",1,"Autocuration",17,"39","CHEMBL3301525","CELL-LINE","NCI-H23",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14795702,1369387,84174,2136593,"=",79.63,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Prostate Cancer cell line DU-145","F","In vitro",,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",17,"50","CHEMBL3301536","CELL-LINE","DU-145",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14796002,1369346,84174,2136593,"=",60.89,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human CNS Cancer cell line SF-539","F","In vitro",,"Homo sapiens",9606,,,"SF-539",,81322,"N",1,"Autocuration",17,"9","CHEMBL3301495","CELL-LINE","SF-539",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14796222,1369356,84174,2136593,"=",68.23,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line SW-620","F","In vitro",,"Homo sapiens",9606,,,"SW-620",,81331,"N",1,"Autocuration",17,"19","CHEMBL3301505","CELL-LINE","SW-620",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14796425,1369366,84174,2136593,"=",84.22,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line MDA-MB-435","F","In vitro",,"Homo sapiens",9606,,,"MDA-MB-435",,81245,"N",1,"Autocuration",17,"29","CHEMBL3301515","CELL-LINE","MDA-MB-435",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14796835,1369377,84174,2136593,"=",41.08,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line NCI-H322M","F","In vitro",,"Homo sapiens",9606,,,"NCI-H322M",,80889,"N",1,"Autocuration",17,"40","CHEMBL3301526","CELL-LINE","NCI-H322M",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14797088,1369388,84174,2136593,"=",57.27,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Prostate Cancer cell line PC-3","F","In vitro",,"Homo sapiens",9606,,,"PC-3",,80390,"N",1,"Autocuration",17,"51","CHEMBL3301537","CELL-LINE","PC-3",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14797813,1369367,84174,2136593,"=",63.44,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line SK-MEL-2","F","In vitro",,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",17,"30","CHEMBL3301516","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14798385,1369347,84174,2136593,"=",14.37,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human CNS Cancer cell line SNB-19","F","In vitro",,"Homo sapiens",9606,,,"SNB-19",,80499,"N",1,"Autocuration",17,"10","CHEMBL3301496","CELL-LINE","SNB-19",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14798608,1369357,84174,2136593,"=",68.4,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Leukemia cell line CCRF-CEM","F","In vitro",,"Homo sapiens",9606,,,"CCRF-CEM",,80064,"N",1,"Autocuration",17,"20","CHEMBL3301506","CELL-LINE","CCRF-CEM",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14799222,1369378,84174,2136593,"=",3.09,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line NCI-H460","F","In vitro",,"Homo sapiens",9606,,,"NCI-H460",,81024,"N",1,"Autocuration",17,"41","CHEMBL3301527","CELL-LINE","NCI-H460",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14799467,1369389,84174,2136593,"=",33.95,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line 786-0","F","In vitro",,"Homo sapiens",9606,,,"786-0",,80640,"N",1,"Autocuration",17,"52","CHEMBL3301538","CELL-LINE","786-0",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14799777,1369348,84174,2136593,"=",-33.0,"%",1,"Inhibition",,"Outside typical range","MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human CNS Cancer cell line SNB-75","F","In vitro",,"Homo sapiens",9606,,,"SNB-75",,81278,"N",1,"Autocuration",17,"11","CHEMBL3301497","CELL-LINE","SNB-75",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14799997,1369358,84174,2136593,"=",89.55,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Leukemia cell line HL-60(TB)","F","In vitro",,"Homo sapiens",9606,,,"HL-60(TB)",,22226,"U",0,"Autocuration",17,"21","CHEMBL3301507","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14800196,1369368,84174,2136593,"=",67.72,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line SK-MEL-28","F","In vitro",,"Homo sapiens",9606,,,"SK-MEL-28",,80485,"N",1,"Autocuration",17,"31","CHEMBL3301517","CELL-LINE","SK-MEL-28",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14800863,1369338,84174,2136593,"=",82.95,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Breast Cancer cell line BT-549","F","In vitro",,"Homo sapiens",9606,,,"BT-549",,81316,"N",1,"Autocuration",17,"1","CHEMBL3301487","CELL-LINE","BT-549",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14801809,1369379,84174,2136593,"=",50.08,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Non-Small Cell Lung Cancer cell line NCI-H522","F","In vitro",,"Homo sapiens",9606,,,"NCI-H522",,81283,"N",1,"Autocuration",17,"42","CHEMBL3301528","CELL-LINE","NCI-H522",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14802059,1369390,84174,2136593,"=",38.85,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line A498","F","In vitro",,"Homo sapiens",9606,,,"A498",,80021,"N",1,"Autocuration",17,"53","CHEMBL3301539","CELL-LINE","A498",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14802503,1369339,84174,2136593,"=",-3.28,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Breast Cancer cell line HS 578T","F","In vitro",,"Homo sapiens",9606,,,"HS 578T",,22226,"U",0,"Autocuration",17,"2","CHEMBL3301488","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14802621,1369349,84174,2136593,"=",32.89,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human CNS Cancer cell line U251","F","In vitro",,"Homo sapiens",9606,,,"U251",,80559,"N",1,"Autocuration",17,"12","CHEMBL3301498","CELL-LINE","U251",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14802842,1369359,84174,2136593,"=",55.52,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Leukemia cell line K-562","F","In vitro",,"Homo sapiens",9606,,,"K-562",,22226,"U",0,"Autocuration",17,"22","CHEMBL3301508","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14803040,1369369,84174,2136593,"=",63.92,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line SK-MEL-5","F","In vitro",,"Homo sapiens",9606,,,"SK-MEL-5",,80488,"N",1,"Autocuration",17,"32","CHEMBL3301518","CELL-LINE","SK-MEL-5",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14803446,1369380,84174,2136593,"=",42.48,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Ovarian Cancer cell line IGROV1","F","In vitro",,"Homo sapiens",9606,,,"IGROV1",,22226,"U",0,"Autocuration",17,"43","CHEMBL3301529","UNCHECKED","Unchecked",,,0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14803703,1369391,84174,2136593,"=",15.57,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Renal Cancer cell line ACHN","F","In vitro",,"Homo sapiens",9606,,,"ACHN",,80025,"N",1,"Autocuration",17,"54","CHEMBL3301540","CELL-LINE","ACHN",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14804264,1369350,84174,2136593,"=",43.61,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Colon Cancer cell line COLO 205","F","In vitro",,"Homo sapiens",9606,,,"COLO 205",,80099,"N",1,"Autocuration",17,"13","CHEMBL3301499","CELL-LINE","COLO 205",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14804486,1369360,84174,2136593,"=",81.78,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Leukemia cell line MOLT-4","F","In vitro",,"Homo sapiens",9606,,,"MOLT-4",,80285,"N",1,"Autocuration",17,"23","CHEMBL3301509","CELL-LINE","MOLT-4",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14804684,1369370,84174,2136593,"=",76.48,"%",1,"Inhibition",,,"MMV: NCI60 panel. Malaria Box compounds were tested for inhibition of the human Melanoma cell line UACC-257","F","In vitro",,"Homo sapiens",9606,,,"UACC-257",,80568,"N",1,"Autocuration",17,"33","CHEMBL3301519","CELL-LINE","UACC-257",9606,"Homo sapiens",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14805255,1369398,84176,2137361,"=",0.0331,,0,"Relative Growth",,,"MMV: Growth assays were conducted using the prototrophic S. cerevisiae strain JHY222. Each MMV compound (0.1 mM) was tested in minimal media containing dextrose as a carbon source (Yeast Nitrogen Base, Dextrose; YNBD). The growth rate in the presence of each MMV compound was calculated as follows: (i) the first 10 OD readings were averaged and subtracted from all OD readings of the corresponding curve to set the baseline of the growth curve to zero, and (ii) the area under the curve (AUC) was then calculated as the sum of all OD readings. AUC was calculated following 80 OD readings, corresponding to roughly 20 h of growth. A ârelative growthâ value was calculated as follows: (AUCDRUG â AUCDMSO)/AUCDMSO; where AUCDMSO represents growth measured in a DMSO control well that was on the same microtiter plate of the drug-treated culture. A relative growth value near zero means the compound had little or no effect on growth, whereas a value near -1 means the compound strongly or completely inhibited growth.","F","In vitro",,"Saccharomyces cerevisiae",4932,,,,,50347,"N",1,"Autocuration",17,"2","CHEMBL3301548","ORGANISM","Saccharomyces cerevisiae",4932,"Saccharomyces cerevisiae",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14805852,1369399,84176,2137361,"=",-0.0366,,0,"Relative Growth",,,"MMV: Growth assays were conducted using the prototrophic S. cerevisiae strain JHY222. Each MMV compound (0.1 mM) was tested in minimal media containing ethanol and glycerol as carbon sources (Yeast Nitrogen Base, Ethanol, Glycerol; YNBEG). The growth rate in the presence of each MMV compound was calculated as follows: (i) the first 10 OD readings were averaged and subtracted from all OD readings of the corresponding curve to set the baseline of the growth curve to zero, and (ii) the area under the curve (AUC) was then calculated as the sum of all OD readings. AUC was calculated following 180 OD readings, corresponding to roughly 45 h of growth. A ârelative growthâ value was calculated as follows: (AUCDRUG â AUCDMSO)/AUCDMSO; where AUCDMSO represents growth measured in a DMSO control well that was on the same microtiter plate of the drug-treated culture. A relative growth value near zero means the compound had little or no effect on growth, whereas a value near -1 means the compound strongly or completely inhibited growth.","F","In vitro",,"Saccharomyces cerevisiae",4932,,,,,50347,"N",1,"Autocuration",17,"3","CHEMBL3301549","ORGANISM","Saccharomyces cerevisiae",4932,"Saccharomyces cerevisiae",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14806131,1369397,84176,2137361,"=",0.0094,,0,"Relative Growth",,,"MMV: Growth assays were conducted using the prototrophic S. cerevisiae strain JHY222. Each MMV compound (0.1 mM) was tested in rich media containing dextrose as a carbon source (Yeast Extract, Peptone, Dextrose; YPD). The growth rate in the presence of each MMV compound was calculated as follows: (i) the first 10 OD readings were averaged and subtracted from all OD readings of the corresponding curve to set the baseline of the growth curve to zero, and (ii) the area under the curve (AUC) was then calculated as the sum of all OD readings. AUC was calculated following 80 OD readings corresponding to roughly 20 h of growth. A ârelative growthâ value was calculated as follows: (AUCDRUG â AUCDMSO)/AUCDMSO; where AUCDMSO represents growth measured in a DMSO control well that was on the same microtiter plate of the drug-treated culture. A relative growth value near zero means the compound had little or no effect on growth, whereas a value near -1 means the compound strongly or completely inhibited growth.","F","In vitro",,"Saccharomyces cerevisiae",4932,,,,,50347,"N",1,"Autocuration",17,"1","CHEMBL3301547","ORGANISM","Saccharomyces cerevisiae",4932,"Saccharomyces cerevisiae",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14806643,1369404,84178,2138294,"=",17.54,"%",0,"Growth Inhibition",,,"MMV: Measure of pLDH activity as indication of parasite viability. Gametocytogenesis of 3D7 Plasmodium falciparum strain was induced in vitro and asexual parasites were depleted with N-acetylglucosamine. Gametocytes were treated with dihydroartemisinin, epoxomicin, methylene blue, primaquine, puromycin or chloroquine in 96-well plates and the pLDH activity was evaluated using a modified Makler protocol. Mosquito infectivity was measured by the standard membrane feeding assay.","F","In vitro",,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",17,"1","CHEMBL3301556","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14807209,1369408,84179,2138890,">",1000.0,"nM",1,"IC50",,,"MMV: MAP2K Protein kinase inhibition assay using recombinant PfMAP2K, protein substrate, ATP and KinaseGlo to measure % inhibition at 1 uM MMV box compound. Final concentrations were 1 ÂµM ATP, 0.5 mM DTT, 1 mM MgCl2, 0.5 mg/mL BSA, and 10 Âµg/ml MAP2 in a buffer of 50 mM HEPES (pH 7.0). 0.5 mg/mL histone III-S served as the substrate (13); 100 ÂµM AMP-PNP, an ATP analog, was used as a control inhibitor. Incubation time was 4 hours.","F","In vitro",,"Plasmodium falciparum",5833,,,,,108432,"D",9,"Autocuration",17,"3","CHEMBL3301565","SINGLE PROTEIN","Mitogen-activated protein kinase",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14807413,1369411,84179,2138890,">",2500.0,"nM",1,"IC50",,,"MMV: ProRS recombinant Plasmodium falciparum Prolyl-tRNA-synthetase, assay with yeast tRNA, ATP, and proline and 3 uM MMV malaria box compound, assay read out with kinase glo as % inhibition.","F","In vitro",,"Plasmodium falciparum",5833,,,,,108433,"H",8,"Autocuration",17,"6","CHEMBL3301568","SINGLE PROTEIN","Proline--tRNA ligase",36329,"Plasmodium falciparum (isolate 3D7)",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14808154,1369412,84179,2138890,">",2500.0,"nM",1,"IC50",,,"MMV: KRS recombinant Plasmodium falciparum Lysyl-tRNA-synthetase, assay with yeast tRNA, ATP, and lysine and 3 uM MMV malaria box compound, assay read out with kinase glo as % inhibition.","F","In vitro",,"Plasmodium falciparum",5833,,,,,108434,"H",8,"Autocuration",17,"7","CHEMBL3301569","SINGLE PROTEIN","Lysine--tRNA ligase",36329,"Plasmodium falciparum (isolate 3D7)",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14808354,1369406,84179,2138890,">",1000.0,"nM",1,"IC50",,,"MMV: PK6 Protein kinase inhibition assay using recombinant PfPK6, Myelin Basic Protein (MBP) substrate, ATP and KinaseGlo to measure % inhibition at 1 uM MMV box compound. Final concentrations were 1.5 ÂµM ATP, 5 mM MnCl2, and 15 Âµg/ml PK6 in a buffer of 100 mM Tris-HCl (pH 7.5). 50 Âµg/mL MBP was provided as the substrate; 10 ÂµM staurosporine was used as a control inhibitor. Incubation time was 3 hours and 40 minutes.The catalytic activity of each kinase was considered proportional to ATP consumed, as determined from measurements of residual [ATP] with the luciferase-based reagent Kinase-Glo (Promega) following incubation. Luminescence (proportional to residual [ATP]) was measured on the plate readers FLx800 (BioTek Instruments, Winooski, VT, USA) and MicroBeta2.","F","In vitro",,"Plasmodium falciparum",5833,,,,,108431,"D",9,"Autocuration",17,"1","CHEMBL3301563","SINGLE PROTEIN","Cdk-related protein kinase 6",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14808558,1369409,84179,2138890,">",1000.0,"nM",1,"IC50",,,"MMV: CDPK1 Protein kinase inhibition assay using recombinant PfCDPK1, syntide 2 peptide substrate, ATP and KinaseGlo to measure % inhibition at 1 uM MMV box compound.","F","In vitro",,"Plasmodium falciparum",5833,,,,,104318,"H",8,"Autocuration",17,"4","CHEMBL3301566","SINGLE PROTEIN","Calcium-dependent protein kinase 1",36329,"Plasmodium falciparum (isolate 3D7)",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14809277,1369407,84179,2138890,">",1000.0,"nM",1,"IC50",,,"MMV: PK7 Protein kinase inhibition assay using recombinant PfPK7, ATP and KinaseGlo to measure % inhibition at 1 uM MMV box compound. Final concentrations were 1 ÂµM ATP, 2 mM DTT, 20 mM MgCl2, 2 mM MnCl2, 0.01% BSA, and 6 Âµg/ml PK7, in a buffer of 20 mM Tris-HCl (pH 7.5). The enzyme itself was the only substrate present (since autophosphorylation occurs); 100 ÂµM 1NA-PP1 was used as a control inhibitor.  Incubation time was 3 hours.","F","In vitro",,"Plasmodium falciparum",5833,,,,,101467,"D",9,"Autocuration",17,"2","CHEMBL3301564","SINGLE PROTEIN","Putative uncharacterized protein pk7",5833,"Plasmodium falciparum",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
583947,"InChI=1S/C22H20N4O/c1-27-18-13-11-17(12-14-18)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-16-7-3-2-4-8-16/h2-14H,15H2,1H3,(H2,23,24,25,26)","COc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171111-3",14809481,1369410,84179,2138890,">",1000.0,"nM",1,"IC50",,,"MMV: CDPK4 Protein kinase inhibition assay using recombinant PfCDPK4, syntide2 peptide substrate, ATP and KinaseGlo to measure % inhibition at 1 uM MMV box compound.","F","In vitro",,"Plasmodium falciparum",5833,,,,,105236,"H",8,"Autocuration",17,"5","CHEMBL3301567","SINGLE PROTEIN","Calcium-dependent protein kinase 4",36329,"Plasmodium falciparum (isolate 3D7)",0,3,126,,"A Active",1.0,0.36,0.35,0.37,1731000,"ENAMINE","Z56833758"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2815378,586268,48285,835982,"=",0.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054502","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2828052,586269,48285,835982,"=",191.91,"nM",1,"XC50",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054503","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2828497,586266,48285,835982,"=",95.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054500","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2832813,586270,48285,835982,"=",6.0,"%",1,"Inhibition",,,"GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.","F",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",2,,"CHEMBL1054504","CELL-LINE","HepG2",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2836441,586271,48285,835982,"=",0.93,"%",1,"IFI",,,"GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested","F",,,,,,,,,22226,"U",0,"Autocuration",2,,"CHEMBL1054505","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",2851655,586267,48285,835982,"=",97.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054501","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3037765,600888,49165,865311,"=",0.0,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3040147,600887,49165,865311,">",100000.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3042648,600886,49165,865311,"=",541.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3043501,600885,49165,865311,"=",621.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3048222,600890,49166,870165,">",15000.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",3051713,600889,49166,870165,,85.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4051814,688739,51887,1064702,"=",25118.9,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ]","B",,"confirmatory","Homo sapiens",9606,,,,,103657,"D",9,"Autocuration",7,"1460","CHEMBL1614421","SINGLE PROTEIN","Microtubule-associated protein tau",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4208633,688239,51887,1211822,"=",29092.9,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells. (Class of assay: confirmatory) ","F",,"confirmatory","Drosophila",7215,,,,,22226,"U",0,"Autocuration",7,"2685","CHEMBL1614459","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4668621,688267,51887,1064702,"=",631.0,"nM",1,"Potency","Not Active",,"PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))]","F",,"confirmatory","Escherichia coli",562,,,,,10027,"H",8,"Intermediate",7,"485294","CHEMBL1614530","SINGLE PROTEIN","Beta-lactamase AmpC",83333,"Escherichia coli K-12",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",4822270,688546,51887,1064702,"=",31622.8,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,20053,"D",9,"Autocuration",7,"902","CHEMBL1613992","SINGLE PROTEIN","Cellular tumor antigen p53",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",5435729,737257,51887,1211822,,25929.0,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648]","F",,"confirmatory","Homo sapiens",9606,,,,,103144,"D",9,"Autocuration",7,"504444","CHEMBL1738184","SINGLE PROTEIN","Nuclear factor erythroid 2-related factor 2",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",5877291,737042,51887,1211822,,4107.8,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125]","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"504467","CHEMBL1738588","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",6873728,752509,51887,1064702,,89125.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504856]","F",,"confirmatory",,,,,,,104173,"D",9,"Autocuration",7,"504845","CHEMBL1794499","SINGLE PROTEIN","Regulator of G-protein signaling 4",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",7146987,752590,51887,1211822,,293.6,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",11380366,845074,51887,1211822,,14068.4,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1: Hit Confirmation using MMS Stimulated ELG1. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624249","CHEMBL2114872","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",11424889,845072,51887,1211822,,887.7,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with 5FU Viability. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624250","CHEMBL2114870","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",11724750,845177,51887,1211822,,354.8,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,11758,"D",9,"Autocuration",7,"624417","CHEMBL2114788","SINGLE PROTEIN","Glucagon-like peptide 1 receptor",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12005206,845241,51887,1211822,,2229.7,"nM",1,"Potency","active",,"PubChem BioAssay. HTS assay for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1: Hit Confirmation. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624248","CHEMBL2114909","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12027133,845261,51887,1211822,,12538.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with Unstimulated Viability Assay. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"624252","CHEMBL2114929","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12820421,954272,51887,1064702,,3662.6,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12840596,954272,51887,1211822,,7307.8,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",12848317,954305,51887,1211822,,14581.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
532400,"InChI=1S/C21H23N5O3/c1-27-11-7-10-22-21-23-16-13-18(29-3)17(28-2)12-15(16)20-24-19(25-26(20)21)14-8-5-4-6-9-14/h4-6,8-9,12-13H,7,10-11H2,1-3H3,(H,22,23)","COCCCNc1nc2cc(OC)c(OC)cc2c3nc(nn13)c4ccccc4","SJ000082805-2",13053391,954305,51887,1064702,,4610.9,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,0,4,727,,"A Active",1.0,0.37,0.36,0.39,35764723,"ENAMINE","Z1157725076"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237271,726822,55744,1335106,"=",93.62,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686422","CELL-LINE","HT-29",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237289,726823,55744,1335106,"=",78.71,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686423","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237307,726824,55744,1335106,"=",93.32,"%",1,"Inhibition",,,"Anticancer activity against human SKOV3 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",1,,"CHEMBL1686424","CELL-LINE","SK-OV-3",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237335,726826,55744,1335106,"=",19650.0,"nM",1,"IC50",,,"Anticancer activity against human DU145 cells by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686426","CELL-LINE","DU-145",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237353,726827,55744,1335106,"=",10060.0,"nM",1,"IC50",,,"Anticancer activity against human HT-29 cells by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686427","CELL-LINE","HT-29",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237381,726831,55744,1335106,"=",53.74,"%",1,"Inhibition",,,"Anticancer activity against human DU145 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686431","CELL-LINE","DU-145",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237389,726832,55744,1335106,"=",77.87,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686432","CELL-LINE","HT-29",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",5237397,726919,55744,1335106,"=",77.62,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686708","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
671608,"InChI=1S/C20H18N4O/c1-14-6-4-7-15(12-14)22-20-23-18-10-3-2-9-17(18)19(24-20)21-13-16-8-5-11-25-16/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1cccc(Nc2nc(NCc3occc3)c4ccccc4n2)c1","SJ000866764-1",14767926,1369280,84147,2131535,,99.93,"%",0,"PPB",,,"% bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.","A","In vitro",,"Homo sapiens",9606,,"Plasma",,,22224,"U",0,"Autocuration",27,"4","CHEMBL3301365","ADMET","ADMET",,,0,5,720,,"A Active",1.0,0.39,0.38,0.41,2412023,"ENAMINE","Z56833757"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3026227,600885,49165,869072,"=",183.7,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3033162,600888,49165,869072,"=",0.0,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3035173,600887,49165,869072,"=",10900.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3036938,600886,49165,869072,"=",240.7,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3051893,600890,49166,871048,,3599.7,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",3052068,600889,49166,871048,,753.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",6233922,752282,57966,1431942,,,,0,"Activity","Active",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",6234092,752283,57966,1431942,"=",277.6,"nM",1,"IC50",,,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
588298,"InChI=1S/C22H20N4/c1-16-11-13-18(14-12-16)24-22-25-20-10-6-5-9-19(20)21(26-22)23-15-17-7-3-2-4-8-17/h2-14H,15H2,1H3,(H2,23,24,25,26)","Cc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000243624-2",6234725,752283,57966,1431942,"=",31.73,"um",0,"Schizont size","50.67 pixels",,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,6,349,,"A Active",1.0,0.41,0.36,0.44,5633666,"ENAMINE","Z56833764"
589104,"InChI=1S/C28H31N3O/c32-24(22-31-27-14-6-4-12-25(27)26-13-5-7-15-28(26)31)21-30-19-17-29(18-20-30)16-8-11-23-9-2-1-3-10-23/h1-15,24,32H,16-22H2/b11-8+","OC(CN1CCN(C\C=C\c2ccccc2)CC1)Cn3c4ccccc4c5ccccc35","SJ000127662-2",3047668,600890,49166,869983,,649.7,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,7,490,,"A Active",1.0,0.43,0.41,0.45,1198684,"CHEMBRIDGE","5236683"
589104,"InChI=1S/C28H31N3O/c32-24(22-31-27-14-6-4-12-25(27)26-13-5-7-15-28(26)31)21-30-19-17-29(18-20-30)16-8-11-23-9-2-1-3-10-23/h1-15,24,32H,16-22H2/b11-8+","OC(CN1CCN(C\C=C\c2ccccc2)CC1)Cn3c4ccccc4c5ccccc35","SJ000127662-2",3051159,600889,49166,869983,,1397.2,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,7,490,,"A Active",1.0,0.43,0.41,0.45,1198684,"CHEMBRIDGE","5236683"
588911,"InChI=1S/C24H21ClN2O5S/c1-4-32-23(30)20-13(2)26-24-27(21(20)14-5-8-17(31-3)9-6-14)22(29)19(33-24)12-15-11-16(25)7-10-18(15)28/h5-12,21,28H,4H2,1-3H3/b19-12-","CCOC(=O)C1=C(C)N=C2S\C(=C/c3cc(Cl)ccc3O)\C(=O)N2C1c4ccc(OC)cc4","SJ000154494-3",3047173,600890,49166,869753,">",15000.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,8,,44,"A Active",0.98,0.44,0.36,0.49,25884268,"CHEMBRIDGE","5832039"
588911,"InChI=1S/C24H21ClN2O5S/c1-4-32-23(30)20-13(2)26-24-27(21(20)14-5-8-17(31-3)9-6-14)22(29)19(33-24)12-15-11-16(25)7-10-18(15)28/h5-12,21,28H,4H2,1-3H3/b19-12-","CCOC(=O)C1=C(C)N=C2S\C(=C/c3cc(Cl)ccc3O)\C(=O)N2C1c4ccc(OC)cc4","SJ000154494-3",3052363,600889,49166,869753,">",15000.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,8,,44,"A Active",0.98,0.44,0.36,0.49,25884268,"CHEMBRIDGE","5832039"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048037,600890,49166,870300,,1542.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048412,600891,49166,870300,,1139.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum 3D7","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730081","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048584,600892,49166,870300,,1440.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum K1","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730641","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048756,600893,49166,870300,,1069.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum V1/S","F",,,"Plasmodium falciparum",5833,"V1/S",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730642","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3048928,600894,49166,870300,">",21708.8,"nM",1,"EC50",,,"ST_JUDE: Growth inhibition of to Toxoplasma gondii, in human U-2OS cells, as measured by luciferase.","F",,,"Toxoplasma gondii",383379,"RH",,,,50472,"N",1,"Autocuration",4,,"CHEMBL730643","ORGANISM","Toxoplasma gondii",5811,"Toxoplasma gondii",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049100,600895,49166,870300,,5622.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of Trypanosoma brucei","F",,,"Trypanosoma brucei",5702,"3D7",,,,50418,"N",1,"Autocuration",4,,"CHEMBL730920","ORGANISM","Trypanosoma brucei",5691,"Trypanosoma brucei",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049250,600898,49166,870300,,4766.8,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial hepatocellular carcinoma cells (HepG2)","T",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",4,,"CHEMBL1038864","CELL-LINE","HepG2",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049422,600899,49166,870300,,8666.1,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial embryonic kidney cells (HEK293)","T",,,"Homo sapiens",9606,,,"HEK293",,80936,"N",1,"Autocuration",4,,"CHEMBL1038865","CELL-LINE","HEK293",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049594,600900,49166,870300,,8220.4,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human Burkitt''s lymphoma lymphoblast cells (Raji)","T",,,"Homo sapiens",9606,,,"Raji",,80414,"N",1,"Autocuration",4,,"CHEMBL1038866","CELL-LINE","Raji",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049739,600903,49166,870300,,305.4,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum SB-A6","F",,,"Plasmodium falciparum",5833,"SB-A6",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038869","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3049911,600904,49166,870300,,1068.1,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum D10 transfected with yeast DHOD","F",,,"Plasmodium falciparum",5833,"D10",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038870","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050009,600896,49166,870300,,8.8,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using Alamar Blue to measure viability of Leishmania major","F",,,"Leishmania major",5664,,,,,50460,"N",1,"Autocuration",4,,"CHEMBL1038862","ORGANISM","Leishmania major",5664,"Leishmania major",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050181,600897,49166,870300,,8409.5,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human foreskin fibroblast cells (BJ)","T",,,"Homo sapiens",9606,,,"BJ",,80704,"N",1,"Autocuration",4,,"CHEMBL1038863","CELL-LINE","BJ",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050508,600901,49166,870300,,651.3,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum Dd2","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038867","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3050680,600902,49166,870300,">",10176.0,"nM",1,"EC50",,,"ST_JUDE: Cytotoxicity against Plasmodium falciparum W2","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",4,,"CHEMBL1038868","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",3051528,600889,49166,870300,,1148.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237270,726822,55744,1335105,"=",92.86,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686422","CELL-LINE","HT-29",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237288,726823,55744,1335105,"=",88.05,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686423","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237306,726824,55744,1335105,"=",91.82,"%",1,"Inhibition",,,"Anticancer activity against human SKOV3 cells assessed as growth inhibition at 100 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-OV-3",,80493,"N",1,"Autocuration",1,,"CHEMBL1686424","CELL-LINE","SK-OV-3",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237334,726826,55744,1335105,"=",19170.0,"nM",1,"IC50",,,"Anticancer activity against human DU145 cells by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686426","CELL-LINE","DU-145",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237352,726827,55744,1335105,"=",16470.0,"nM",1,"IC50",,,"Anticancer activity against human HT-29 cells by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686427","CELL-LINE","HT-29",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237380,726831,55744,1335105,"=",57.95,"%",1,"Inhibition",,,"Anticancer activity against human DU145 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"DU-145",,80125,"N",1,"Autocuration",1,,"CHEMBL1686431","CELL-LINE","DU-145",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237388,726832,55744,1335105,"=",83.27,"%",1,"Inhibition",,,"Anticancer activity against human HT-29 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"HT-29",,80166,"N",1,"Autocuration",1,,"CHEMBL1686432","CELL-LINE","HT-29",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589373,"InChI=1S/C23H22N4O/c1-2-28-19-14-12-18(13-15-19)25-23-26-21-11-7-6-10-20(21)22(27-23)24-16-17-8-4-3-5-9-17/h3-15H,2,16H2,1H3,(H2,24,25,26,27)","CCOc1ccc(Nc2nc(NCc3ccccc3)c4ccccc4n2)cc1","SJ000171307-4",5237396,726919,55744,1335105,"=",91.58,"%",1,"Inhibition",,,"Anticancer activity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM by MTT assay","F",,,"Homo sapiens",9606,,,"SK-MEL-2",,80482,"N",1,"Autocuration",1,,"CHEMBL1686708","CELL-LINE","SK-MEL-2",9606,"Homo sapiens",0,10,310,,"A Active",1.0,0.52,0.47,0.59,6296699,"ENAMINE","Z56833777"
589864,"InChI=1S/C17H19ClN2O2S/c1-21-15-8-7-12(11-16(15)22-2)9-10-19-17(23)20-14-6-4-3-5-13(14)18/h3-8,11H,9-10H2,1-2H3,(H2,19,20,23)","COc1ccc(CCNC(=S)Nc2ccccc2Cl)cc1OC","SJ000180705-2",3047545,600890,49166,870876,,1358.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,11,589,425,"A Active",1.0,0.59,0.55,0.61,2194279,"CHEMBRIDGE","7202723"
589864,"InChI=1S/C17H19ClN2O2S/c1-21-15-8-7-12(11-16(15)22-2)9-10-19-17(23)20-14-6-4-3-5-13(14)18/h3-8,11H,9-10H2,1-2H3,(H2,19,20,23)","COc1ccc(CCNC(=S)Nc2ccccc2Cl)cc1OC","SJ000180705-2",3051036,600889,49166,870876,,1289.6,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,11,589,425,"A Active",1.0,0.59,0.55,0.61,2194279,"CHEMBRIDGE","7202723"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",6882642,752493,51887,1491577,,39810.7,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623]","F",,"confirmatory",,,,,,,100972,"D",9,"Autocuration",7,"588590","CHEMBL1794483","SINGLE PROTEIN","DNA polymerase iota",9606,"Homo sapiens",0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",6894739,752496,51887,1491577,,39810.7,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813]","F",,"confirmatory",,,,,,,100144,"D",9,"Autocuration",7,"588795","CHEMBL1794486","SINGLE PROTEIN","Flap endonuclease 1",9606,"Homo sapiens",0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",6958343,752563,51887,1491577,,7079.5,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860]","F",,"confirmatory","Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",7,"588856","CHEMBL1794553","CELL-LINE","HepG2",9606,"Homo sapiens",0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",7025962,752546,51887,1491577,,50118.7,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Kappa. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588638]","F",,"confirmatory",,,,,,,100932,"D",9,"Autocuration",7,"588579","CHEMBL1794536","SINGLE PROTEIN","DNA polymerase kappa",9606,"Homo sapiens",0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",7250901,752594,51887,1491577,,2511.9,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860]","F",,"confirmatory",,,,,,,103691,"D",9,"Autocuration",7,"588855","CHEMBL1794584","SINGLE PROTEIN","Mothers against decapentaplegic homolog 3",9606,"Homo sapiens",0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",11468172,845105,51887,1491577,,2818.4,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,22226,"U",0,"Autocuration",7,"624263","CHEMBL2114716","UNCHECKED","Unchecked",,,0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",12894732,954272,51887,1491577,,100.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",13150197,954305,51887,1491577,,89.1,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",13162488,954333,51887,1491577,,14125.4,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,102780,"D",9,"Autocuration",7,"652106","CHEMBL2354282","SINGLE PROTEIN","Alpha-synuclein",9606,"Homo sapiens",0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",14061565,1301460,51887,1491577,,10000.0,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720579","CHEMBL3215017","UNCHECKED","Unchecked",,,0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
1038596,"InChI=1S/C20H21N2/c1-21(2)18-12-8-16(9-13-18)10-14-19-15-11-17-6-4-5-7-20(17)22(19)3/h4-15H,1-3H3/q+1","CN(C)c1ccc(\C=C\c2ccc3ccccc3[n+]2C)cc1","SJ000866797-1",14313605,1301709,51887,1491577,,10000.0,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720580","CHEMBL3215270","UNCHECKED","Unchecked",,,0,12,868,,"A Active",0.97,0.76,0.58,1.3,207143011,"ENAMINE","Z56758412"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2814452,586268,48285,839902,"=",1.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054502","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2817881,586271,48285,839902,"=",4.64,"%",1,"IFI",,,"GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested","F",,,,,,,,,22226,"U",0,"Autocuration",2,,"CHEMBL1054505","UNCHECKED","Unchecked",,,0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2825727,586267,48285,839902,"=",60.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"Dd2",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054501","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2847278,586270,48285,839902,"=",42.0,"%",1,"Inhibition",,,"GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.","F",,,"Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",2,,"CHEMBL1054504","CELL-LINE","HepG2",9606,"Homo sapiens",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2860384,586269,48285,839902,"=",891.91,"nM",1,"XC50",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054503","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",2878772,586266,48285,839902,"=",88.0,"%",1,"Inhibition",,,"GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",2,,"CHEMBL1054500","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3034302,600888,49165,869434,"=",13.43,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3036311,600887,49165,869434,">",10000.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3038093,600886,49165,869434,"=",160.4,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",3039346,600885,49165,869434,">",1303.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
539495,"InChI=1S/C21H15Cl2N3O/c22-14-7-9-15(17(23)12-14)20(26-18-5-1-2-10-24-18)16-8-6-13-4-3-11-25-19(13)21(16)27/h1-12,20,27H,(H,24,26)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(Cl)cc4Cl","SJ000866810-1",6235272,752282,57966,1430581,,,,0,"Activity","Inactive",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,13,100,,"A Active",0.99,0.84,0.74,1.0,2145149,"ENAMINE","Z56842924"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3024979,600885,49165,868330,"=",548.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3031897,600888,49165,868330,"=",7.14,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3033912,600887,49165,868330,"=",15600.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",3035663,600886,49165,868330,"=",529.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
587620,"InChI=1S/C20H18N4O/c1-14-7-2-4-10-17(14)22-20-23-18-11-5-3-9-16(18)19(24-20)21-13-15-8-6-12-25-15/h2-12H,13H2,1H3,(H2,21,22,23,24)","Cc1ccccc1Nc2nc(NCc3occc3)c4ccccc4n2","SJ000170251-2",6232787,752282,57966,1431065,,,,0,"Activity","Inactive",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,14,460,,"A Active",1.0,0.85,0.8,0.92,2167069,"ENAMINE","Z56833785"
589605,"InChI=1S/C17H13ClF6N2O3/c18-10-1-3-11(4-2-10)25-15(27)26-12-5-13(28-8-16(19,20)21)7-14(6-12)29-9-17(22,23)24/h1-7H,8-9H2,(H2,25,26,27)","FC(F)(F)COc1cc(NC(=O)Nc2ccc(Cl)cc2)cc(OCC(F)(F)F)c1","SJ000281068-2",3048252,600890,49166,870572,,465.7,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,17,733,,"A Active",0.99,1.3,1.2,1.5,2941320,"ENAMINE","Z56798855"
589605,"InChI=1S/C17H13ClF6N2O3/c18-10-1-3-11(4-2-10)25-15(27)26-12-5-13(28-8-16(19,20)21)7-14(6-12)29-9-17(22,23)24/h1-7H,8-9H2,(H2,25,26,27)","FC(F)(F)COc1cc(NC(=O)Nc2ccc(Cl)cc2)cc(OCC(F)(F)F)c1","SJ000281068-2",3051743,600889,49166,870572,,1358.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,17,733,,"A Active",0.99,1.3,1.2,1.5,2941320,"ENAMINE","Z56798855"
589547,"InChI=1S/C20H19ClN2O2/c21-16-6-3-15(4-7-16)19(23-10-12-25-13-11-23)17-8-5-14-2-1-9-22-18(14)20(17)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccc(Cl)cc4","SJ000243592-3",3047335,600890,49166,870503,,2971.4,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,19,542,144,"A Active",1.0,2.0,1.9,2.1,2943453,"ENAMINE","Z56174631"
589547,"InChI=1S/C20H19ClN2O2/c21-16-6-3-15(4-7-16)19(23-10-12-25-13-11-23)17-8-5-14-2-1-9-22-18(14)20(17)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccc(Cl)cc4","SJ000243592-3",3050826,600889,49166,870503,,2185.6,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,19,542,144,"A Active",1.0,2.0,1.9,2.1,2943453,"ENAMINE","Z56174631"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",1605716,321687,30155,401749,"=",9120.11,"nM",1,"IC50",,,"Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)","B",,,"Rattus norvegicus",10116,,,,,12832,"H",6,"Expert",1,,"CHEMBL872182","SINGLE PROTEIN","Androgen Receptor",10116,"Rattus norvegicus",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",3048251,600890,49166,870571,,3596.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",3051742,600889,49166,870571,,3953.4,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",6445225,752332,51887,1508549,,6309.6,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule agonists of retinoid X receptor alpha signaling. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,275,"D",9,"Autocuration",7,"588544","CHEMBL1794371","SINGLE PROTEIN","Retinoid X receptor alpha",9606,"Homo sapiens",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",7014953,752570,51887,1508549,,44668.4,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of androgen receptor signaling. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,56,"D",9,"Autocuration",7,"588516","CHEMBL1794560","SINGLE PROTEIN","Androgen Receptor",9606,"Homo sapiens",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",7048653,752552,51887,1508549,,35481.3,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of estrogen receptor alpha signaling. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,19,"D",9,"Autocuration",7,"588513","CHEMBL1794542","SINGLE PROTEIN","Estrogen receptor alpha",9606,"Homo sapiens",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",7224290,752302,51887,1508549,,50118.7,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,133,"D",9,"Autocuration",7,"588536","CHEMBL1794293","SINGLE PROTEIN","Peroxisome proliferator-activated receptor gamma",9606,"Homo sapiens",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",11425253,845092,51887,1508549,,54482.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103144,"D",9,"Autocuration",7,"651741","CHEMBL2114890","SINGLE PROTEIN","Nuclear factor erythroid 2-related factor 2",9606,"Homo sapiens",0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14016923,1301454,51887,2042988,,60882.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743086","CHEMBL3215011","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14021022,1301482,51887,2042988,,17312.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743225","CHEMBL3215043","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14023856,1301476,51887,2042988,,48792.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743211","CHEMBL3215037","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14024080,1301482,51887,2046433,,61644.8,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743225","CHEMBL3215043","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14029671,1301476,51887,2046433,,54941.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743211","CHEMBL3215037","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14049137,1301483,51887,2042988,,9735.4,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743035","CHEMBL3215044","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14051329,1301468,51887,2042988,,48360.3,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743042","CHEMBL3215029","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14054667,1301483,51887,2046433,,6916.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743035","CHEMBL3215044","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14056885,1301468,51887,2046433,,30637.9,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743042","CHEMBL3215029","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14083462,1301431,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720691","CHEMBL3214956","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14084029,1301447,51887,2042988,,121.5,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743079","CHEMBL3215004","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14084740,1301431,51887,2046433,,54941.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720691","CHEMBL3214956","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14087346,1301447,51887,2046433,,77.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743079","CHEMBL3215004","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14101493,1301536,51887,2042988,,54261.1,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule agonists of the p53 signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"651631","CHEMBL3215097","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14108411,1301516,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720693","CHEMBL3215077","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14112201,1301516,51887,2046433,,61644.8,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720693","CHEMBL3215077","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14112688,1301536,51887,2046433,,68589.6,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule agonists of the p53 signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"651631","CHEMBL3215097","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14130643,1301512,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743075","CHEMBL3215073","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14141911,1301512,51887,2046433,,54941.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743075","CHEMBL3215073","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14142693,1301543,51887,2042988,,48792.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743213","CHEMBL3215104","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14150118,1301543,51887,2046433,,38895.2,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743213","CHEMBL3215104","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14153574,1301573,51887,2046433,,6859.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for small molecule disruptors of the mitochondrial membrane potential.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720635","CHEMBL3215134","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14160893,1301562,51887,2042988,,60882.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743064","CHEMBL3215123","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14161329,1301581,51887,2042988,,54746.1,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743218","CHEMBL3215142","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14164331,1301551,51887,1508549,,44668.4,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720659","CHEMBL3215112","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14179818,1301573,51887,2042988,,6088.2,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for small molecule disruptors of the mitochondrial membrane potential.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720635","CHEMBL3215134","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14190307,1301548,51887,2046433,,68589.6,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743202","CHEMBL3215109","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14201680,1301562,51887,2046433,,61130.6,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743064","CHEMBL3215123","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14206102,1301581,51887,2046433,,54941.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743218","CHEMBL3215142","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14208963,1301548,51887,2042988,,68310.7,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743202","CHEMBL3215109","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14217080,1301631,51887,2046433,,48557.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743080","CHEMBL3215192","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14228451,1301644,51887,2046433,,6916.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743191","CHEMBL3215205","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14231901,1301631,51887,2042988,,54261.1,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743080","CHEMBL3215192","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14238817,1301622,51887,2046433,,27306.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743065","CHEMBL3215183","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14239611,1301644,51887,2042988,,12256.1,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743191","CHEMBL3215205","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14242167,1301670,51887,2042988,,54746.1,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743212","CHEMBL3215231","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14260351,1301662,51887,2046433,,68589.6,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743041","CHEMBL3215223","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14260913,1301622,51887,2042988,,27195.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743065","CHEMBL3215183","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14261312,1301640,51887,2046433,,68589.6,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743203","CHEMBL3215201","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14268735,1301640,51887,2042988,,68310.7,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743203","CHEMBL3215201","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14275497,1301707,51887,2046433,,61644.8,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743036","CHEMBL3215268","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14289749,1301676,51887,2046433,,48966.2,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743033","CHEMBL3215237","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14300816,1301676,51887,2042988,,34542.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743033","CHEMBL3215237","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14308492,1301691,51887,2042988,,54746.1,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743221","CHEMBL3215252","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14332802,1301788,51887,2046433,,21872.4,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720692","CHEMBL3214835","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14334333,1301753,51887,2046433,,61644.8,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule activators of the heat shock response signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743210","CHEMBL3214800","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14343843,1301778,51887,2042988,,60882.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743014","CHEMBL3214825","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14347792,1301788,51887,2042988,,8676.7,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720692","CHEMBL3214835","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14353277,1301764,51887,2046433,,977.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743069","CHEMBL3214811","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14360402,1301752,51887,2046433,,54941.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743074","CHEMBL3214799","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14368108,1301760,51887,2046433,,54941.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743222","CHEMBL3214807","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14372158,1301764,51887,2042988,,614.3,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743069","CHEMBL3214811","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14375360,1301752,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743074","CHEMBL3214799","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14377197,1301778,51887,2046433,,48557.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743014","CHEMBL3214825","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14391217,1301808,51887,2042988,,43486.4,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743194","CHEMBL3214855","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14395110,1301818,51887,2042988,,60882.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify aromatase inhibitors - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743084","CHEMBL3214865","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14399404,1301835,51887,2046433,,19331.2,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743015","CHEMBL3214882","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14399827,1301858,51887,2042988,,68310.7,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743012","CHEMBL3214905","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14410329,1301822,51887,2046433,,54941.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743224","CHEMBL3214869","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14413588,1301807,51887,2046433,,61644.8,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743217","CHEMBL3214854","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14419151,1301868,51887,2046433,,61130.6,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"651633","CHEMBL3214915","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14421569,1301822,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743224","CHEMBL3214869","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14422057,1301835,51887,2042988,,60882.0,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743015","CHEMBL3214882","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14424592,1301798,51887,2046433,,61130.6,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay to identify aromatase inhibitors.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743083","CHEMBL3214845","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14424721,1301807,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743217","CHEMBL3214854","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14430381,1301868,51887,2042988,,68310.7,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"651633","CHEMBL3214915","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14433403,1301858,51887,2046433,,24336.5,"nM",1,"Potency","active",,"PubChem BioAssay. qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743012","CHEMBL3214905","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14439761,1301808,51887,2046433,,38895.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743194","CHEMBL3214855","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14443271,1301798,51887,2042988,,54261.1,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify aromatase inhibitors.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743083","CHEMBL3214845","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14443664,1301818,51887,2046433,,61130.6,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify aromatase inhibitors - cell viability counter screen.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743084","CHEMBL3214865","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14444053,1301825,51887,2042988,,61426.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"743215","CHEMBL3214872","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14449241,1301894,51887,2046433,,19331.2,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability.   (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720634","CHEMBL3214971","UNCHECKED","Unchecked",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
328174,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl","SJ000143975-2",14766629,1369278,84147,2127711,,3.86,,0,"LogD7.4",,,"Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5","P",,,,,,,,,22224,"U",0,"Autocuration",27,"2","CHEMBL3301363","ADMET","ADMET",,,0,20,892,,"A Active",1.0,2.3,2.2,2.5,520984,"CHEMBRIDGE","7145315"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",3048068,600890,49166,870353,,486.0,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",3051559,600889,49166,870353,,1021.9,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",5621689,737137,51887,1346837,,461.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485345, AID485355]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"493014","CHEMBL1737902","UNCHECKED","Unchecked",,,0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",5771345,737344,51887,1346837,,3162.3,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404]","F",,"confirmatory","Homo sapiens",9606,,,,,102672,"D",9,"Autocuration",7,"504332","CHEMBL1738442","SINGLE PROTEIN","Histone-lysine N-methyltransferase, H3 lysine-9 specific 3",9606,"Homo sapiens",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",5844390,736947,51887,1346837,,89125.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391]","F",,"confirmatory","Homo sapiens",9606,,,,,104016,"D",9,"Autocuration",7,"504333","CHEMBL1738312","SINGLE PROTEIN","Bromodomain adjacent to zinc finger domain protein 2B",9606,"Homo sapiens",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",6471993,752320,51887,1346837,,141253.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"540263","CHEMBL1794359","UNCHECKED","Unchecked",,,0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",6811608,752411,51887,1346837,,89125.1,"nM",1,"Potency","inactive",,"PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962]","F",,"confirmatory",,,,,,,103989,"D",9,"Autocuration",7,"540317","CHEMBL1794401","SINGLE PROTEIN","Chromobox protein homolog 1",9606,"Homo sapiens",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",7087740,752590,51887,1346837,,1471.6,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",7384017,752313,51887,1346837,,8492.1,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411]","F",,"confirmatory",,,,,,,101018,"D",9,"Autocuration",7,"588342","CHEMBL1794352","SINGLE PROTEIN","Luciferin 4-monooxygenase",7054,"Photinus pyralis",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",11295371,845045,51887,1346837,,29092.9,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103711,"D",9,"Autocuration",7,"624296","CHEMBL2114843","SINGLE PROTEIN","Geminin",9606,"Homo sapiens",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",11759063,845177,51887,1346837,,7079.5,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,11758,"D",9,"Autocuration",7,"624417","CHEMBL2114788","SINGLE PROTEIN","Glucagon-like peptide 1 receptor",9606,"Homo sapiens",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",11881194,845199,51887,1346837,,11220.2,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,100791,"D",9,"Autocuration",7,"624287","CHEMBL2114810","SINGLE PROTEIN","Guanine nucleotide-binding protein G(s), subunit alpha",9606,"Homo sapiens",0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589421,"InChI=1S/C18H21ClN2O/c19-17-6-7-18(22)16(12-17)14-21-10-8-20(9-11-21)13-15-4-2-1-3-5-15/h1-7,12,22H,8-11,13-14H2","Oc1ccc(Cl)cc1CN2CCN(Cc3ccccc3)CC2","SJ000147376-2",13168045,954305,51887,1346837,,29092.9,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,0,21,489,,"A Active",0.97,2.4,1.8,3.4,2073213,"CHEMBRIDGE","5431762"
589027,"InChI=1S/C13H9Cl3N2O/c14-8-1-3-11(4-2-8)17-13(19)18-12-6-9(15)5-10(16)7-12/h1-7H,(H2,17,18,19)","Clc1ccc(NC(=O)Nc2cc(Cl)cc(Cl)c2)cc1","SJ000144869-2",3047863,600890,49166,869890,,1632.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,22,946,,"A Active",1.0,3.0,2.9,3.3,2063305,"CHEMBRIDGE","5320781"
589027,"InChI=1S/C13H9Cl3N2O/c14-8-1-3-11(4-2-8)17-13(19)18-12-6-9(15)5-10(16)7-12/h1-7H,(H2,17,18,19)","Clc1ccc(NC(=O)Nc2cc(Cl)cc(Cl)c2)cc1","SJ000144869-2",3051354,600889,49166,869890,,3213.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,22,946,,"A Active",1.0,3.0,2.9,3.3,2063305,"CHEMBRIDGE","5320781"
1369535,"InChI=1S/C22H17F2N3O2/c23-22(24)29-16-9-6-15(7-10-16)19(27-18-5-1-2-12-25-18)17-11-8-14-4-3-13-26-20(14)21(17)28/h1-13,19,22,28H,(H,25,27)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4ccc(OC(F)F)cc4","SJ000866779-1",11033943,842698,65070,1679280,">",10420.0,"nM",1,"IC50",,,"DNDI: Inhibition of Human African Trypanosomiasis (HAT), STIB 795, in vitro","F","In vitro",,"Trypanosoma brucei brucei",5702,"STIB 795",,,,50420,"N",1,"Autocuration",14,"1007605","CHEMBL2095144","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",0,23,,456,"A Active",0.98,3.2,2.7,3.9,2936350,"ENAMINE","Z56794778"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",3047617,600890,49166,870967,,5592.3,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,24,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",3051108,600889,49166,870967,,3759.2,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,24,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",11033739,842698,65070,1679141,"=",4020.0,"nM",1,"IC50",,,"DNDI: Inhibition of Human African Trypanosomiasis (HAT), STIB 795, in vitro","F","In vitro",,"Trypanosoma brucei brucei",5702,"STIB 795",,,,50420,"N",1,"Autocuration",14,"1007605","CHEMBL2095144","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",0,24,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
589946,"InChI=1S/C21H16ClN3O2/c22-15-8-5-14(6-9-15)18(25-21-17(26)4-2-12-24-21)16-10-7-13-3-1-11-23-19(13)20(16)27/h1-12,18,26-27H,(H,24,25)","Oc1cccnc1NC(c2ccc(Cl)cc2)c3ccc4cccnc4c3O","SJ000113373-3",11033740,842697,65070,1679141,">",41670.0,"nM",1,"IC50",,,"DNDI: Cytotoxicity against human MRC-5 lung fibroblast cells.","T","In vitro",,"Homo sapiens",9606,,,"MRC5",,80291,"U",0,"Autocuration",14,"1002458","CHEMBL2095143","CELL-LINE","MRC5",9606,"Homo sapiens",0,24,670,,"A Active",1.0,3.7,3.4,4.1,2581715,"ENAMINE","Z56865460"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3629276,688416,51887,1219954,"=",6511.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus. (Class of assay: confirmatory) [Related pubchem assays: 1900 (Counter Screen), 1677 (Project Summary), 1902 (Retest at Dose), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus",1301,,,,,50024,"N",1,"Autocuration",7,"1915","CHEMBL1614538","ORGANISM","Streptococcus",1301,"Streptococcus",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3694989,688469,51887,1219954,"=",10512.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of Luciferase Translation or Activity in H4 Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1813 (Primary HTS), 1827 (Project Summary)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1990","CHEMBL1613869","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3771747,688537,51887,1219954,"=",558.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus. (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus",1301,,,,,50775,"N",1,"Autocuration",7,"1900","CHEMBL1613983","ORGANISM","Streptococcus sp. 'group A'",36470,"Streptococcus sp. 'group A'",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",3830184,688810,51887,1219954,"=",3288.5,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Modulators of miRNAs and/or Activators of miR-21. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103763,"M",3,"Autocuration",7,"2288","CHEMBL1613836","NUCLEIC-ACID","microRNA 21",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4112376,688759,51887,1219954,"=",891.3,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) ","F",,"confirmatory","Mus musculus",10090,,,,,103664,"D",9,"Autocuration",7,"2546","CHEMBL1614441","SINGLE PROTEIN","Nuclear receptor ROR-gamma",10090,"Mus musculus",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4125408,688233,51887,1219954,"=",6540.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS Screen to Identify Cytotoxic Compounds of NIH3T3 cells. (Class of assay: confirmatory) [Related pubchem assays: 1885, 1968 ]","F",,"confirmatory",,,,,"NIH3T3",,22226,"U",0,"Autocuration",7,"2010","CHEMBL1614453","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4128672,688235,51887,1219954,"=",21010.0,"nM",1,"IC50","Active",,"PUBCHEM_BIOASSAY: A Counter Screen to identiry small molecule screen for inhibitors of the PhoP region in Salmonella Typhimurium. (Class of assay: confirmatory) [Related pubchem assays: 2253, 1863, 1981, 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2401","CHEMBL1614455","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4264864,688239,51887,1219954,"=",18356.4,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells. (Class of assay: confirmatory) ","F",,"confirmatory","Drosophila",7215,,,,,22226,"U",0,"Autocuration",7,"2685","CHEMBL1614459","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4303810,688118,51887,1219954,"=",30190.0,"nM",1,"IC50","Active",,"PUBCHEM_BIOASSAY: A screen for inhibitors of the PhoP region in Salmonella Typhimurium using a modified counterscreen. (Class of assay: confirmatory) [Related pubchem assays: 2253, 1863, 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1981","CHEMBL1614127","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4315166,688128,51887,1219954,"=",631.0,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)]","F",,"confirmatory","Schistosoma mansoni",6183,,,,,102962,"D",9,"Autocuration",7,"485364","CHEMBL1614161","SINGLE PROTEIN","Thioredoxin glutathione reductase",6183,"Schistosoma mansoni",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4333126,688131,51887,1219954,"=",666.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Retest of Candida albicans Growth in the Presence of Fluconazole. (Class of assay: confirmatory) [Related pubchem assays: 2007 (Project Summary), 1979 (Primary HTS)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2467","CHEMBL1614164","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4389601,688186,51887,1219954,"=",2960.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: A cytotoxicity screen of small molecule inhibitors of the PhoP region in Salmonella Typhimurium identified in the primary screen. (Class of assay: confirmatory) [Related pubchem assays: 1863, 1981, 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2253","CHEMBL1614312","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4396093,688141,51887,1219954,"=",44668.4,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) ","F",,"confirmatory","Bacillus subtilis",1423,,,,,103681,"D",9,"Autocuration",7,"1490","CHEMBL1614174","SINGLE PROTEIN","4'-phosphopantetheinyl transferase ffp",1423,"Bacillus subtilis",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4399138,688181,51887,1219954,"=",1316.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of Trypanosoma cruzi Replication. (Class of assay: confirmatory) [Related pubchem assays: 1885, 1968 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2044","CHEMBL1614307","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4441301,688157,51887,1219954,"=",6309.6,"nM",1,"Potency","Not Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) ","F",,"confirmatory","Influenza A virus (A/WSN/1933(H1N1))",382835,,,,,103736,"D",9,"Autocuration",7,"2326","CHEMBL1614236","SINGLE PROTEIN","Nonstructural protein 1",382835,"Influenza A virus",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4488955,688170,51887,1219954,"=",39810.7,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)]","B",,"confirmatory","Equus caballus",9796,,,,,103687,"D",9,"Autocuration",7,"485281","CHEMBL1614249","SINGLE PROTEIN","Ferritin light chain",9796,"Equus caballus",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4686389,688274,51887,1219954,"=",33980.0,"nM",1,"IC50","Active",,"PUBCHEM_BIOASSAY: A small molecule screen for inhibitors of the PhoP region in Salmonella Typhimurium. (Class of assay: confirmatory) [Related pubchem assays: 2253, 1981, 1874 ]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1863","CHEMBL1613789","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4884259,688653,51887,1219954,"=",3288.5,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103763,"M",3,"Autocuration",7,"2289","CHEMBL1614146","NUCLEIC-ACID","microRNA 21",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4901700,688597,51887,1219954,"=",682.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity. (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus pyogenes M1 GAS",160490,,,,,103661,"H",8,"Autocuration",7,"1902","CHEMBL1614064","SINGLE PROTEIN","Streptokinase A",301447,"Streptococcus pyogenes serotype M1",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4947467,688620,51887,1219954,"=",398.1,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) ","F",,"confirmatory","Mus musculus",10090,,,,,103664,"D",9,"Autocuration",7,"2551","CHEMBL1614087","SINGLE PROTEIN","Nuclear receptor ROR-gamma",10090,"Mus musculus",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4958254,688648,51887,1219954,">",150000.0,"nM",1,"EC50","Not Active","Outside typical range","PUBCHEM_BIOASSAY: Absorbance Microorganism-Based Dose Response HTS to Identify Inhibitors of Streptokinase Expression. (Class of assay: confirmatory) [Related pubchem assays: 1677 (Project Summary), 1902 (Retest at Dose), 1900 (Counter Screen), 1662 (Primary HTS)]","F",,"confirmatory","Streptococcus pyogenes M1 GAS",160490,,,,,103661,"H",8,"Autocuration",7,"1914","CHEMBL1614141","SINGLE PROTEIN","Streptokinase A",301447,"Streptococcus pyogenes serotype M1",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4964328,688623,51887,1219954,"=",9299.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Response HTS to Identify Inhibitors of 5&apos;UTR Stem-Loop Driven Prion Protein mRNA Translation in H4 Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1827 (Project Summary), 1813 (Primary HTS)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1994","CHEMBL1614090","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",4982303,688644,51887,1219954,"=",8866.0,"nM",1,"EC50","Active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Confirmation HTS to Identify Inhibitors of of 5&apos;UTR Stem-Loop Driven Alpha-Synuclein mRNA Translation in H4 Neuroglioblastoma Cells. (Class of assay: confirmatory) [Related pubchem assays: 1827 (Project Summary), 1813 (Primary HTS)]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"1988","CHEMBL1614137","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5345146,737185,51887,1219954,,28183.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1473, AID2293, AID2577, AID2578, AID2587, AID2588, AID2589, AID2590, AID2592, AID2593, AID2595, AID2596, AID2597, AID2613, AID2671, AID488845]","F",,"confirmatory","Homo sapiens",9606,,,,,10733,"D",9,"Autocuration",7,"2101","CHEMBL1613818","SINGLE PROTEIN","Beta-glucocerebrosidase",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5556965,737623,51887,1219954,,31622.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709]","F",,"confirmatory","Homo sapiens",9606,,,,,20053,"D",9,"Autocuration",7,"504706","CHEMBL1738132","SINGLE PROTEIN","Cellular tumor antigen p53",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5618250,737137,51887,1219954,,35481.3,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485345, AID485355]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"493014","CHEMBL1737902","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5692514,737298,51887,1219954,">",118576.0,"nM",1,"IC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Absorbance-based bacterial cell-based high throughput dose response assay for inhibitors of AddAB recombination protein complex. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435030, AID449728, AID449731, AID488942, AID488955, AID488956]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"492959","CHEMBL1738325","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5740966,737344,51887,1219954,,11220.2,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404]","F",,"confirmatory","Homo sapiens",9606,,,,,102672,"D",9,"Autocuration",7,"504332","CHEMBL1738442","SINGLE PROTEIN","Histone-lysine N-methyltransferase, H3 lysine-9 specific 3",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5791231,737425,51887,1219954,"=",105490.0,"nM",1,"IC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput dose response assay for inhibitors of bacterial viability. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435030, AID449728, AID449731, AID488942, AID488955, AID488956]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"492958","CHEMBL1738643","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5821301,736947,51887,1219954,,39810.7,"nM",1,"Potency","Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391]","F",,"confirmatory","Homo sapiens",9606,,,,,104016,"D",9,"Autocuration",7,"504333","CHEMBL1738312","SINGLE PROTEIN","Bromodomain adjacent to zinc finger domain protein 2B",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5921021,737042,51887,1219954,,16353.5,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125]","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"504467","CHEMBL1738588","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",5978668,737110,51887,1219954,">",118576.0,"nM",1,"IC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput dose response assay to identify inhibitors of RecBCD. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435030, AID449728, AID449731, AID488942, AID488955, AID488956]","F",,"confirmatory","Escherichia coli str. K-12 substr. MG1655",511145,,,,,104804,"H",6,"Autocuration",7,"492957","CHEMBL1737858","PROTEIN COMPLEX","Exodeoxyribonuclease V",83333,"Escherichia coli (strain K12)",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6432176,688444,51887,1219954,"=",787.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Secondary Assay to Identify Inhibitors of Resistant C. albicans Growth in the Presence of Fluconazole. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007]","F",,"confirmatory",,,,,,,103684,"H",8,"Autocuration",7,"2423","CHEMBL1613820","SINGLE PROTEIN","ATP-dependent molecular chaperone HSP82",294748,"Candida albicans (strain WO-1) (Yeast)",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6555241,752386,51887,1219954,"=",11900.0,"nM",1,"AC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Free Homogeneous Secondary Screen to Identify Inhibitors of DnaB-Intein Splicing Activity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2223, AID489010, AID492950]","F",,"confirmatory",,,,,,,103988,"H",8,"Autocuration",7,"449749","CHEMBL1794324","SINGLE PROTEIN","Replicative DNA helicase",1773,"Mycobacterium tuberculosis",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6698547,752407,51887,1219954,,3696.4,"nM",1,"Potency","active",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504834","CHEMBL1794345","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6773009,752436,51887,1219954,"=",932.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Free Homogeneous Dose Retest to Identify Inhibitors of RecA-Intein Splicing Activity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2097, AID2223, AID489010, AID492950]","F",,"confirmatory",,,,,,,103967,"H",8,"Autocuration",7,"435010","CHEMBL1794426","SINGLE PROTEIN","Protein RecA",1773,"Mycobacterium tuberculosis",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6773335,688696,51887,1219954,"=",2447.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Secondary Assay to Measure Toxicity of Compounds Not in the Presence of Fluconazole. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007, AID434946]","F",,"confirmatory",,,,,,,103684,"H",8,"Autocuration",7,"2387","CHEMBL1614288","SINGLE PROTEIN","ATP-dependent molecular chaperone HSP82",294748,"Candida albicans (strain WO-1) (Yeast)",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",6847600,752506,51887,1219954,"=",3178.0,"nM",1,"AC50","active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Dose Retest to Confirm Inhibitors of Beta Cell Apoptosis. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID435005, AID435007]","F",,"confirmatory",,,,,"INS1",,80764,"N",1,"Autocuration",7,"449756","CHEMBL1794496","CELL-LINE","INS1",10116,"Rattus norvegicus",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7001352,752581,51887,1219954,"=",6721.0,"nM",1,"EC50","active",,"PUBCHEM_BIOASSAY: Luminescence Cell-Based Secondary Assay to Identify Inhibitors of Hsp90. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007, AID434938]","F",,"confirmatory",,,,,,,103684,"H",8,"Autocuration",7,"2400","CHEMBL1794571","SINGLE PROTEIN","ATP-dependent molecular chaperone HSP82",294748,"Candida albicans (strain WO-1) (Yeast)",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7056217,688210,51887,1219954,">",180000.0,"nM",1,"EC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Luminescence Cell-Based Secondary Assay to Identify Inhibitors of Calcineurin. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007]","F",,"confirmatory",,,,,,,103704,"D",9,"Autocuration",7,"2388","CHEMBL1614385","SINGLE PROTEIN","Serine/threonine-protein phosphatase",573826,"Candida dubliniensis (strain CD36 / CBS 7987 / NCPF 3949 / NRRLY-17841) (Yeast)",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7123514,752590,51887,1219954,,13115.4,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7330078,688279,51887,1219954,"=",10912.0,"nM",1,"EC50","inconclusive",,"PUBCHEM_BIOASSAY: Fluorescence Cell-Based Secondary Assay for toxicity in mammalian fibroblasts. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1979, AID2007]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"2327","CHEMBL1613794","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",7391871,752310,51887,1219954,">",380000.0,"nM",1,"AC50","inactive","Outside typical range","PUBCHEM_BIOASSAY: Fluorescence Cell-Free Homogeneous Secondary Screen to Identify Non-Covalent Inhibitors of RecA-Intein Splicing Activity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2223, AID489010, AID492950]","F",,"confirmatory",,,,,,,103988,"H",8,"Autocuration",7,"449750","CHEMBL1794349","SINGLE PROTEIN","Replicative DNA helicase",1773,"Mycobacterium tuberculosis",0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",14020439,1301458,51887,1219954,,2060.0,"nM",1,"AC50","active",,"PubChem BioAssay. Alphascreen Interference Assay Measured in Biochemical System Using Plate Reader - 2160-02_Inhibitor_Dose_CherryPick_Activity.   (Class of assay: confirmatory) ","B",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720494","CHEMBL3215015","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
775426,"InChI=1S/C22H21ClF3N3O/c1-28-9-11-29(12-10-28)20(14-4-6-15(7-5-14)22(24,25)26)17-13-18(23)16-3-2-8-27-19(16)21(17)30/h2-8,13,20,30H,9-12H2,1H3","CN1CCN(CC1)C(c2ccc(cc2)C(F)(F)F)c3cc(Cl)c4cccnc4c3O","SJ000399327-2",14343447,1301770,51887,1219954,,1540.0,"nM",1,"AC50","active",,"PubChem BioAssay. Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_Dose_CherryPick_Activity.   (Class of assay: confirmatory) ","B",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"720495","CHEMBL3214817","UNCHECKED","Unchecked",,,0,25,,617,"A Active",0.99,9.2,8.6,10.0,3554709,"ENAMINE","Z57213753"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3034207,600888,49165,869339,"=",4.35,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3036216,600887,49165,869339,">",22840.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3037998,600886,49165,869339,"=",400.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",3039251,600885,49165,869339,"=",267.2,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",6233758,752283,57966,1431901,"=",146.7,"nM",1,"IC50",,,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",6233881,752282,57966,1431901,,,,0,"Activity","Active",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
588539,"InChI=1S/C20H16BrN3O2/c1-12-10-17(24-26-12)23-18(14-4-2-6-15(21)11-14)16-8-7-13-5-3-9-22-19(13)20(16)25/h2-11,18,25H,1H3,(H,23,24)","Cc1onc(NC(c2cccc(Br)c2)c3ccc4cccnc4c3O)c1","SJ000866800-1",6234684,752283,57966,1431901,"=",16.28,"um",0,"Schizont size","26.00 pixels",,"NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"2","CHEMBL1789906","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,26,,714,"B Active",0.99,1.9,1.6,2.0,2984448,"ENAMINE","Z56175984"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3037611,600888,49165,865157,"=",7.69,"%",1,"IFI",,,"NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.","F",,,,,,,,,22226,"U",0,"Autocuration",3,,"CHEMBL1040694","UNCHECKED","Unchecked",,,0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3039993,600887,49165,865157,">",61220.0,"nM",1,"CC50",,,"NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)","T",,,"Homo sapiens",9606,,,"Huh-7 ",,80169,"N",1,"Autocuration",3,,"CHEMBL1040693","CELL-LINE","Huh-7 ",9606,"Homo sapiens",0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3041414,600886,49165,865157,"=",405.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay","F",,,"Plasmodium falciparum",5833,"W2",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040692","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3042563,600885,49165,865157,"=",365.0,"nM",1,"EC50",,,"NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",3,,"CHEMBL1040691","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3046975,600890,49166,871145,,3029.8,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",3052165,600889,49166,871145,,2998.5,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
584722,"InChI=1S/C18H15IN2O2/c1-12-16(11-22)15-7-2-3-8-17(15)21(12)10-18(23)20-14-6-4-5-13(19)9-14/h2-9,11H,10H2,1H3,(H,20,23)","Cc1c(C=O)c2ccccc2n1CC(=O)Nc3cccc(I)c3","SJ000192808-2",6236452,752282,57966,1434393,,,,0,"Activity","Inactive",,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","F","In vitro",,"Plasmodium yoelii",5861,,,"HepG2-A16-CD81",,50474,"N",1,"Expert",3,"1","CHEMBL1789905","ORGANISM","Plasmodium yoelii",5861,"Plasmodium yoelii",0,27,958,,"B Active",0.99,2.6,2.3,2.7,2467735,"CHEMBRIDGE","7772305"
589478,"InChI=1S/C26H25N3O2/c30-26-22(14-13-18-8-6-16-28-25(18)26)24(29-23-12-3-4-15-27-23)19-7-5-11-21(17-19)31-20-9-1-2-10-20/h3-8,11-17,20,24,30H,1-2,9-10H2,(H,27,29)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(OC5CCCC5)c4","SJ000137729-2",3047274,600890,49166,870420,,4159.1,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"K1",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730080","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,29,913,128,"B Active",1.0,9.0,6.8,9.2,2007839,"CHEMBRIDGE","7925786"
589478,"InChI=1S/C26H25N3O2/c30-26-22(14-13-18-8-6-16-28-25(18)26)24(29-23-12-3-4-15-27-23)19-7-5-11-21(17-19)31-20-9-1-2-10-20/h3-8,11-17,20,24,30H,1-2,9-10H2,(H,27,29)","Oc1c(ccc2cccnc12)C(Nc3ccccn3)c4cccc(OC5CCCC5)c4","SJ000137729-2",3050765,600889,49166,870420,,3714.4,"nM",1,"EC50",,,"ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye","F",,,"Plasmodium falciparum",5833,"3D7",,,,50425,"N",1,"Autocuration",4,,"CHEMBL730079","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,29,913,128,"B Active",1.0,9.0,6.8,9.2,2007839,"CHEMBRIDGE","7925786"
1369300,"InChI=1S/C20H19ClN2O2/c21-17-6-2-1-5-15(17)19(23-10-12-25-13-11-23)16-8-7-14-4-3-9-22-18(14)20(16)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccccc4Cl","SJ000866799-1",11033482,842697,65070,1678976,">",20830.0,"nM",1,"IC50",,,"DNDI: Cytotoxicity against human MRC-5 lung fibroblast cells.","T","In vitro",,"Homo sapiens",9606,,,"MRC5",,80291,"U",0,"Autocuration",14,"1002458","CHEMBL2095143","CELL-LINE","MRC5",9606,"Homo sapiens",0,30,989,546,"B Active",0.98,9.5,8.4,10.0,1092384,"ENAMINE","Z56830583"
1369300,"InChI=1S/C20H19ClN2O2/c21-17-6-2-1-5-15(17)19(23-10-12-25-13-11-23)16-8-7-14-4-3-9-22-18(14)20(16)24/h1-9,19,24H,10-13H2","Oc1c(ccc2cccnc12)C(N3CCOCC3)c4ccccc4Cl","SJ000866799-1",11033483,842698,65070,1678976,"=",5590.0,"nM",1,"IC50",,,"DNDI: Inhibition of Human African Trypanosomiasis (HAT), STIB 795, in vitro","F","In vitro",,"Trypanosoma brucei brucei",5702,"STIB 795",,,,50420,"N",1,"Autocuration",14,"1007605","CHEMBL2095144","ORGANISM","Trypanosoma brucei brucei",5702,"Trypanosoma brucei brucei",0,30,989,546,"B Active",0.98,9.5,8.4,10.0,1092384,"ENAMINE","Z56830583"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",3616849,688409,51887,1137230,"=",22387.2,"nM",1,"Potency","Not Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104677,"D",5,"Autocuration",7,"1766","CHEMBL1614531","PROTEIN-PROTEIN INTERACTION","Menin/Histone-lysine N-methyltransferase MLL",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",3660891,688422,51887,1137230,"=",4466.8,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103668,"D",9,"Autocuration",7,"1487","CHEMBL1614544","SINGLE PROTEIN","Prelamin-A/C",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",3785143,688382,51887,1137230,"=",35481.3,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)]","F",,"confirmatory","Homo sapiens",9606,,,,,103732,"D",9,"Autocuration",7,"2662","CHEMBL1614410","SINGLE PROTEIN","Histone-lysine N-methyltransferase MLL",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",3961305,688779,51887,1137230,"=",12589.3,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ]","F",,"confirmatory",,,,,,,103657,"H",8,"Autocuration",7,"1463","CHEMBL1614502","SINGLE PROTEIN","Microtubule-associated protein tau",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",4065277,688739,51887,1137230,"=",12589.3,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ]","B",,"confirmatory","Homo sapiens",9606,,,,,103657,"D",9,"Autocuration",7,"1460","CHEMBL1614421","SINGLE PROTEIN","Microtubule-associated protein tau",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",4101319,688759,51887,1137230,"=",35481.3,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) ","F",,"confirmatory","Mus musculus",10090,,,,,103664,"D",9,"Autocuration",7,"2546","CHEMBL1614441","SINGLE PROTEIN","Nuclear receptor ROR-gamma",10090,"Mus musculus",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",4570684,688317,51887,1137230,"=",19952.6,"nM",1,"Potency","Not Active",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104677,"D",5,"Autocuration",7,"1768","CHEMBL1614257","PROTEIN-PROTEIN INTERACTION","Menin/Histone-lysine N-methyltransferase MLL",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",4999801,688620,51887,1137230,"=",35481.3,"nM",1,"Potency","Inconclusive",,"PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) ","F",,"confirmatory","Mus musculus",10090,,,,,103664,"D",9,"Autocuration",7,"2551","CHEMBL1614087","SINGLE PROTEIN","Nuclear receptor ROR-gamma",10090,"Mus musculus",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",5401380,737190,51887,1137230,,20596.2,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504444]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"504648","CHEMBL1737994","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",5804802,736947,51887,1137230,,79432.8,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391]","F",,"confirmatory","Homo sapiens",9606,,,,,104016,"D",9,"Autocuration",7,"504333","CHEMBL1738312","SINGLE PROTEIN","Bromodomain adjacent to zinc finger domain protein 2B",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",5894685,737042,51887,1137230,,29081.0,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125]","F",,"confirmatory","Homo sapiens",9606,,,,,104005,"D",9,"Autocuration",7,"504467","CHEMBL1738588","SINGLE PROTEIN","ATPase family AAA domain-containing protein 5",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",6461830,752320,51887,1137230,,44668.4,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"540263","CHEMBL1794359","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",6520654,752407,51887,1137230,,1852.6,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504834","CHEMBL1794345","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",6740254,752471,51887,1137230,,39810.7,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262]","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"540253","CHEMBL1794461","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",7017095,752563,51887,1137230,,8912.5,"nM",1,"Potency","inactive",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860]","F",,"confirmatory","Homo sapiens",9606,,,"HepG2",,81020,"N",1,"Autocuration",7,"588856","CHEMBL1794553","CELL-LINE","HepG2",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",7110989,752590,51887,1137230,,14715.7,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850]","F",,"confirmatory","Plasmodium falciparum",5833,,,,,50425,"U",0,"Autocuration",7,"504832","CHEMBL1794580","ORGANISM","Plasmodium falciparum",5833,"Plasmodium falciparum",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",7357863,752344,51887,1137230,,29081.0,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249]","F",,"confirmatory","Homo sapiens",9606,,,"HEK293",,80936,"N",1,"Autocuration",7,"540256","CHEMBL1794308","CELL-LINE","HEK293",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",7458407,752359,51887,1137230,,29081.0,"nM",1,"Potency","inconclusive",,"PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278]","B",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"540276","CHEMBL1794375","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11307017,845045,51887,1137230,,18356.4,"nM",1,"Potency","active",,"PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103711,"D",9,"Autocuration",7,"624296","CHEMBL2114843","SINGLE PROTEIN","Geminin",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11534797,845164,51887,1137230,,794.3,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS Assay for Inhibitors of Hepatitis C Virus (HCV). (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"U",0,"Autocuration",7,"651820","CHEMBL2114775","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11605057,845169,51887,1137230,,4109.5,"nM",1,"Potency","active",,"PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,"SW480",,103711,"D",9,"Autocuration",7,"624297","CHEMBL2114780","SINGLE PROTEIN","Geminin",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11663518,845173,51887,1137230,,35481.3,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,104167,"D",9,"Autocuration",7,"651635","CHEMBL2114784","SINGLE PROTEIN","Ataxin-2",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11714356,845177,51887,1137230,,10000.0,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,11758,"D",9,"Autocuration",7,"624417","CHEMBL2114788","SINGLE PROTEIN","Glucagon-like peptide 1 receptor",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11852656,752595,51887,1137230,,35481.3,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,12883,"D",9,"Autocuration",7,"504891","CHEMBL1794585","SINGLE PROTEIN","Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11965103,845245,51887,1137230,,12589.3,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,105133,"D",9,"Autocuration",7,"624291","CHEMBL2114913","SINGLE PROTEIN","Glycoprotein hormones alpha chain",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",11981674,845256,51887,1137230,,31622.8,"nM",1,"Potency","inactive",,"PubChem BioAssay. qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction. (Class of assay: confirmatory) ","F",,"confirmatory","Homo sapiens",9606,,,,,103638,"D",9,"Autocuration",7,"624246","CHEMBL2114924","SINGLE PROTEIN","Transcriptional regulator ERG",9606,"Homo sapiens",0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",12916027,954272,51887,1137230,,23109.3,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686978","CHEMBL2354221","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
1698948,"InChI=1S/C19H23NO5S/c1-19(2,3)15(21)10-16-20-18(22)14(26-16)9-11-7-12(23-4)17(25-6)13(8-11)24-5/h7-10H,1-6H3,(H,20,22)/b14-9-,16-10-","COc1cc(\C=C\2/S\C(=C/C(=O)C(C)(C)C)\NC2=O)cc(OC)c1OC","SJ000389261-2",13000051,954305,51887,1137230,,23109.3,"nM",1,"Potency","inconclusive",,"PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) ","F",,"confirmatory",,,,,,,22226,"N",0,"Autocuration",7,"686979","CHEMBL2354254","UNCHECKED","Unchecked",,,0,31,,998,"C Partial",0.8,6.0,3.7,19.0,45561635,"ENAMINE","Z46615665"
